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ABSTRACT 
Breast cancer is the most common cancer among women. Of all breast cancers cases, 
approximately 30 percent have amplification of the self-antigen HER2/neu. Later studies 
demonstrated that HER2/neu-specific antibody and T cell responses were found in HER2/neu-
positive breast cancer patients, indicating HER2/neu is a good target for active immunotherapy. 
A humanized anti HER2/neu antibody trastuzumab, was developed and found to be an effective 
therapy for HER2/neu. However, acquired antibody resistance occurs sooner or later in antibody 
treated patients. Such limitations of antibody therapy provoked scientists into the search for other 
therapeutic strategies. HER2/neu-targeted immunotherapeutic strategies, including vaccines 
using tumor lysates, protein/peptide, DNA, adenoviral vectors (AdV) and dendritic cells (DCs) 
pulsed with the above reagents, have been shown to be effective in experimental models. 
However, they have also been proven to be incapable of breaking tolerance towards HER2/neu 
in clinical trials and eliciting then have not elicited adequate antitumor immunity in curing 
HER2/neu positive breast cancer in transgenic mice with HER2/neu-specific immune tolerance, 
although both humoral and cellular immune responses could be detected.  
CD4+ helper T (Th) cells play crucial roles in priming, expansion and memory of both humoral 
and CD8+ cytotoxic T lymphocyte (CTL) responses. Therefore, they are essential in antitumor 
immunity. The tetanus toxoid Th epitope 947-967 P30, FNNFTVSFWLRVPKVSASHLE, has 
been found to be a universal epitope in sensitizing and proliferating CD4+ T cells ex vivo. OVA-
P30 peptide vaccine could break CD8+ and CD4+ T cell tolerances against the neo-self-antigen 
OVA; it was able to protect transgenic rat insulin promoter (RIP)-mOVA mice from tumor 
growth.  
Adenovirus-based vaccines are able to induce high frequencies of transgene product-specific 
CD8+ T cell responses. In this study, we immunized C57BL/6 mice with OVA-expressing 
AdVOVA. We found that AdVOVA induced sustained OVA-specific CTL responses, leading to 
preventive antitumor immunity against OVA-expressing BL6-10OVA tumor cell challenge in 
wild-type C57BL/6 mice. In addition, we also immunized transgenic FVBneuN mice with neu-
expressing AdVneu. We found that AdVneu vaccination induced neu-specific CTL responses, 
leading to partial reduction of breast carcinogenesis in FVBneuN mice.  
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To assess whether the foreign Th epitope P30 enhances CD4+ and CD8+ T cell responses, we  
constructed another two recombinant AdVs (AdVOVA-P30 and AdVneu-P30),  expressing OVA-P30 
and HER2/neu-P30 gene, respectively. We transfected C57BL/6 mouse bone marrow dendritic 
cells (DCs) with AdVOVA and AdVOVA-P30 for preparation of DCOVA and DCOVA-P30 vaccines.  We 
immunized C57BL/6 mice with DCOVA and DCOVA-P30 and then assessed CD4+ and CD8+ T cell 
responses and antitumor immunity subsequent to immunization. We demonstrated that both 
DCOVA and DCOVA-P30 were capable of stimulating both enhanced CD4+ and CD8+ T cell 
responses, leading to preventive antitumor immunity against challenge of OVA-expressing BL6-
10OVA tumor in 100% (8/8) of the immunized mice. However, DCOVA-P30 induced more efficient 
CD4+ and CD8+ T cell responses than DCOVA, leading to significant reduction of growth of 3 
day-established lung tumor metastasis in C57BL/6 mice, indicating that the foreign CD4+ Th 
epitope P30 can enhance both CD4+ and CD8+ T cell responses. In this study, we also transfected 
transgenic FVBneuN mouse bone marrow DCs with AdVneu and AdVneu-P30 for preparation of 
DCneu and DCneu-P30 vaccines.  We immunized transgenic FVBneuN mice with DCneu and DCneu-
P30 and then assessed CD4+ and CD8+ T cell responses and antitumor immunity subsequent to 
immunization. We demonstrated that DCneu-P30 but not DCneu was capable of stimulating both 
enhanced CD4+ and CD8+ T cell responses, leading to preventive antitumor immunity against 
challenge with 0.3×106 neu-expressing Tg1-1 tumor cells in 100% (8/8) immunized transgenic 
FVBneuN mice; this significantly reduced lung metastasis tumor colonies in  immunized 
transgenic FVBneuN mice challenged with 1×106 Tg1-1 tumor cells, confirming that 
incooperation of foreign CD4+ Th epitope P30  into DC-based vaccines can at least partially 
break self-immune tolerance, leading to enhanced CTL responses and antitumor immunity in 
transgenic FVBneuN mice. 
Taken together, our data demonstrate that the CD4+ Th epitope P30 can enhance both CD4+ and 
CD8+ T cell responses, leading to enhanced DC-stimulated antitumor immunity. This may have 
impact in designing new DC-based vaccines for treatment of breast cancer and other types of 
human malignancies. 
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 1 
1   Introduction 
1.1    Basic immunology  
1.1.1    Innate immunity 
The non-specific innate immune response is the first line of defense against pathogens. Usually, 
it takes place on the first day of pathogen infection. Innate immunity includes the prevention and 
control of infection, and the elimination of infected cells. It also contributes to the elimination of 
stressed host cells and provides warning signals to stimulate adaptive immunity. These functions 
are achieved by its components including physical and chemical barriers (i.e., skin, mucosa, 
blood-brain barriers; antimicrobial chemicals), effector cells like phagocytic cells (i.e., 
neutrophils, mononuclear phagocytes and dendritic cells), natural killer cells (NK), as well as 
blood proteins (i.e. complement) and cytokines.  
Innate immune responses can be triggered by the recognitions of the pathogen associated 
molecular patterns (PAMPs) on pathogens by cell associated pattern recognition receptors (i.e. 
Toll-like receptors (TLRs) or C-type lectin), which send transduction signals or take up the 
pathogen (i.e. pentraxins or collectins). 
Phagocytes are the most numerous effector cells in the innate immune system. They function 
during the identification, ingestion and destruction of microbes. Mononuclear phagocytes play a 
central role in both innate and adaptive immunities. They are derived from bone marrow (BM), 
and enter the peripheral blood as monocytes, and mature as macrophages. Phagocytosis follows 
the recognition of microbes with the binding of cell receptors to PAMPs, or the opsonization of 
microbes by protein coating. Activated phagocytes can destroy phagocytosed microbes by 
releasing proteolytic enzymes into phagolysomes or by releasing reactive oxygen species (ROS). 
Phagocytes can also play a role in antitumor immunity. Macrophages may recognize tumor 
surface antigens via the activating receptor NKG2D, which is also found on natural killer cells 
(NKs) (Diefenbach et al. 2001). Macrophages can be activated by interferon-γ (IFN-γ) secreting 
tumor-specific T cells or NK cells. The mechanisms that kill tumor cells are the same as those 
used to kill infectious microbes. 
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Natural killer cells are another important effector cell type in innate immunity. After recognition 
of microbes, NKs mediate cytotoxicity of infected cells by producing and releasing granule 
proteins (i.e., perforin or granuzyme) to adjacent target cells and initiating apoptosis of infected 
cells. NK cells can also release IFN-γ and activate macrophages to kill phagocytosed microbes. 
NK can also kill tumor cells (Bauer et al. 1999; Groh et al. 1999) that lack major 
histocompatibility complexes (MHC) but express NK2D ligands, i.e. MHC-related protein A and 
B (MICA, MICB). In addition, the inhibitory NK ligand has been detected in breast cancer cell 
lines. Soluble HLA-G is also related to apoptosis of T cells. Altogether, PAMPs, toll-like 
receptors (TLRs) and cells in the innate immune system are potential candidates to be used as 
adjuncts in antitumor immunotherapeutics.  
1.1.2.   Adaptive immunity 
Adaptive immunity happens later than the innate immune responses. It has memories and is more 
specific. It consists of cellular immunity and humoral immunity. Adaptive immune responses 
need a series of steps to develop. In each step, different molecules, immune cells and specialized 
lymphoid tissues are involved. The immune cells include antigen-presenting cells (APCs, such as 
dendritic cells, mononuclear phagocytes; B cells; folicular dendritic cells), lymphocytes (such as 
CD4+ T, CD8+ T and B lymphocytes). Lymphoid tissues include primary (generative) lymphoid 
organs and secondary (peripheral) lymphoid organs. Primary lymphoid organs consist of bone 
marrow, where progenitors of lymphocytes and blood cells reside, and thymus, where central 
tolerance is induced through positive and negative selection of T cells. Secondary lymphoid 
organs include the spleen, lymph nodes, mucosa (Peyer’s patches), respiratory airways and the 
skin; in these organs the naïve lymphocytes meet foreign antigens presented by APCs, become 
activated to undergo clonal expansion, and induce peripheral (foreign antigen) tolerance. 
Molecules involved in adaptive immunity include cytokines, complement, immunoglobulin 
super-families (such as MHC molecules, antibodies/immunoglobulins, T cell receptors (TCR) 
and B cell receptors (BCR)). These molecules are critical for specificity, signal transduction, and 
cell homing. For example, immunoglobulins are encoded by genes that can be re-arranged and 
play an essential role in B lymphocyte diversification.  
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1.1.2.1   Humoral immunity 
Humoral immunity is mediated by antibodies, produced by B cells, which function to defend 
against extracellular microbes and microbial toxins. B cells derived from bone marrow stem cells 
meet pathogens in peripheral organs and become differentiated into plasma cells. Short-lived, 
antibody secreting plasma cells can travel around the body to perform their effector functions. 
Long-lived antibody secreting plasma cells can travel back to bone marrow or reside at the port 
of infection as memory cells; here they can magnify immune responses to fight against infection 
caused by the same antigen. The main effector function of humoral immunity, conveyed by 
antibodies, is neutralization. It blocks the binding of microbe/microbial toxins to receptors in 
host cells, therefore inhibiting infections by the microbe.  It can also facilitate phagocytosis by 
binding of IgG Fc to Fc receptors on phagocytes after opsonization of microbes. Alternatively, it 
can induce antibody dependent cellular cytotoxicity (ADCC) by coating infectious cells. Another 
important function of antibodies is the activation of complement by the classical and alternative 
pathways, which induce the killing of microbes through the molecule attacking complex (MAC).  
Humoral immunity plays a critical role in mucosal immunity and especially neonatal immunity. 
The dominant antibody in the mucosal system is IgA. Its main function is the neutralization of 
microbes by blocking their entry into host cells. Since neonates lack an effective immune 
response against microbes, passive humoral immunity by placental transfer of maternal 
antibodies, IgA and IgG, is critical for the prevention of infection in new bone infants. In 
antitumor immunity, antibodies can be utilized to fight cancers either by activating MACs, or by 
ADCC.  
1.1.2.2   Cellular immunity 
In contrast to humoral immune response, the cellular immune response is triggered mainly by the 
recognition of a peptide-major histocompatibility complex (pMHC), which is a MHC molecule 
and an epitope of a foreign antigen on antigen presenting cells. The major histocompatibility 
complex was discovered as the determinant of tissue transplant and later found to be involved in 
the presentation of antigens to lymphocytes in the immune responses. In humans, it is called the 
human leukocyte antigen (HLA).  It is encoded by a polymorphic gene located on chromosome 
17, which determines class I molecules, class II molecules, and several proteins, such as 
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transporters associated with antigen processing (TAP), all play critical roles in antigen 
presenting.  
MHC molecules are required for antigen presenting to T lymphocytes but not in the 
discrimination of a foreign and self-antigens. Both MHC-I and MHC-II molecules are similar in 
molecular structure, but different in the components that determine the types of T lymphocytes 
they activate. They both consist of two non-covalently associated polypeptide chains. The MHC-
I molecule consists of a 44-47 kD α-chain (α1, α2, α3) and a 12 kD β2-microglubulin; α1 and α2 
form a peptide-binding cleft of 8-11amino acid (aa) peptides. The MHC-II molecule consists of a 
32-34 kD α-chain (α1, α2, α3) and a 29-32 kD β-chain; α1 and β2 form a peptide-binding cleft 
for peptides of approximately 25aa. The MHC-I molecule is expressed constitutively on all 
nucleated cells, while the MHC-II molecule is expressed only on antigen presenting cells, such 
as dendritic cells, B lymphocytes, macrophages and others. Both MHC-I and MHC-II lead to 
different antigen presentation through either the exogenous pathway or endogenous pathway, and 
stimulate different types of lymphocytes leading to different immune responses. 
 
Fig. 1-1 The structure of class I and class II, MHC molecules. Each consists of an 
extracellular peptide-binding groove, immunoglobulin-like domains and transmembrane and 
cytoplasmic domains; Class I MHC molecule consist of two noncovalently linked polypeptide 
chains, α chain (including α1 domain, α2 domain, α3 domain) and β2-microglobulin; Class II 
MHC molecule consist of two noncovalently associated polypeptide chains, α chain (including 
α1 domain, α2 domain) and β chain ((including β 1 domain, β 2 domain). Class I and II molecules 
can bind to 8~11 aa peptide and ~25 aa peptide respectively. 
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In the endogenous pathway, with the aid of TAP, foreign antigens and self-peptides in APCs can 
be transported into the endoplasmic reticulum (ER), processed by the proteasome and then 
cleaved into 8-11 aa peptide. These peptides are then loaded into the cleft of MHC-I molecule to 
form pMHC-I complex, the complex is then transported to the cell surface, where it activates 
CD8+ T cells by the interaction of pMHC-I and TCR on CD8+ T cells (Germain 1995; Abbas et 
al. 2000). 
In the exogenous pathway, antigens from the extracellular environment are taken up by APCs 
through endocytosis or phagocytosis. Then, they are degraded by enzymatic proteins in 
endosomes or lysosomes, generating ~25aa peptides. These peptides and newly synthesized 
MHC-II complexes combine as pMHC-II molecules, which are transported to cell surfaces of 
APCs to interact with TCR on CD4+ T helper cells (Germain 1995; Watts 2004). It is important 
to note that cross-presentation to MHC-I can occur in the exogenous pathway. 
In addition to antigen processing and presentation, an effective cellular immune response 
requires at least two signals (Bretscher and Cohn 1970). One signal is from the interaction of 
costimulatory molecules such as B7-1 (CD80), B7-2 (CD86) on APCs with receptors (CD28) on 
responding T cells. Another signal is provided by cytokines that are secreted from either APCs or 
activated T cells, which activate and stimulate proliferation and differentiation of effector T 
lymphocytes and B-lymphocytes, as well as other cells in innate immunity (Heath and Carbone 
2001; Ackerman and Cresswell 2004). A lack of antigen presention or a lack of provision of the 
second signal, mediated by co-stimulators, was found to lead to immune tolerance or anergy to 
that specific antigen (Hicklin et al. 1998; Wang et al. 1999). Following antigen presentation, 
naïve lymphocytes become active, and undergo a series of steps for specific T lymphocyte clonal 
expansion, differentiation, and migration. The two types of T cells, activated by pMHC-I and 
pMHC-II, are (1) the effector CD8+ T lymphocytes or cytotoxic T lymphocytes (CTLs) and (2) 
the effector CD4+ T lymphocytes, mediating two different cellular immune responses. 
CTLs are effective in eliminating intracellular microbes by killing infected cells. The mechanism 
of CTL mediated cytotoxicity (CTL response) is antigen specific and contact dependent. CTLs 
are activated by the binding of antigen specific T-cell receptors as well as CD8 co-receptors to 
pHMC-I on target cells. With the aid of the interaction of adhesion molecules on each cell, CTLs 
 6 
and target cells form stable contacts. At the site of the contacts, CTLs kill the target cells by 
delivering cytotoxic proteins to the target cells. 
The immune reactions mediated by effector CD4+ T lymphocytes are diverse.  Different subsets 
of effector CD4+ T lymphocytes that produce different cytokines may be induced. The immune 
responses against microbes within phagocytes are modulated by CD4+ T helper-1, also called 
Th-1 cells. Phagocytes can act as APCs and present microbe antigens to CD4+ T cells. Receiving 
the 2nd signal from the interaction between the co-stimulator (CD40) and the T cell receptor on T 
cells, naïve CD4+ T cells become mature and secrete IFN-γ, which stimulates the cytotoxicity of 
phagocytes as well as CD4+ T helper dependant CTL responses. APCs also activate CD4+ T 
helper-1 (Th-1) cells to secrete cytokines that stimulate B cells to produce antibodies, which can 
lead to opsonization and phagocytosis of microbes. CD4+ T helper-2, also called Th-2 cells, can 
mediate humoral immune responses against helminthic infection by secreting cytokines that 
induce the secretion of coating antibody IgE and eosinophil/mast cell-mediated immune 
responses. 
1.2     Tumor immunology  
1.2.1    Immune tolerance 
In antitumor immunity, tumor antigen-specific CD8+ CTLs are effective in the killing of tumor 
cells. As tumor cells do not express MHC-II molecules or co-stimulators, professional APCs 
such as dendritic cells are needed. Tumor-associated antigens (TAAs) can be cross-presented by 
APCs to CD4+ T cells to promote the differentiation and proliferation of cytotoxic CD8+ T 
lymphocytes. 
Immunological tolerance is important in the prevention of autoimmunity but it can lead to tumor 
development. The mechanism for induction of immune tolerance provides information on how 
immune responses are generated in eliminating tumor cells or how immune responses are down-
regulated in organ/tissue transplantation.  
During T cell development, lymphocytes undergo central tolerance, such that lymphocytes that 
recognize self-antigens with high affinity are induced to undergo apoptosis through death 
receptor or mitochondrial pathways. In central tolerance for T lymphocytes, CD4+CD8+ double 
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positive T cells go through positive selection in the thymus cortex; they meet self-antigens and 
are either eliminated if no reaction take place or develop into two main types of signal positive T 
cells (CD4+ T cells or CD8+ T cells), depending on the type of MHC molecule. The newly 
generated signal-positive T cells then go through negative selection in the thymus medulla; T 
cells, recognizing self-antigens with high affinity are eliminated; the remaining T cells survive as 
a naïve/unresponsive T cell for immune surveiliance. Mature lymphocytes in peripheral tissues 
also develop peripheral tolerance if they are capable of responding to tissue specific antigens. 
Most of the knowledge about peripheral tolerance is based on CD4+ T cells. Active CD4+ T cells 
can be induced to become functionally unresponsive via the lack of a 2nd signal provided by co-
stimulators or the lack of potent innate immune responses. CD4+CD25+ T cells, when they are 
exposed to self-antigens, can convert to regulatory T cells (Sakaguchi et al. 2010). 
1.2.2    Immuno-surveillance, immuno-editing and tumor antigens  
Early in the 1950s, Burnet and Thomas proposed a concept called “immuno-surveillance”, 
wherein lymphocytes patrolling the body can recognize and destroy clones of transformed cells 
before they grow into tumors (Burnet 1957). When knockout mice were available two decades 
later, tumors were found in these mice because of a lack of necessary immune elements (Kaplan 
et al. 1998; Street et al. 2001; Shankaran et al. 2001). The basic concept was renamed “cancer 
immunoediting” (Dunn et al. 2004), which included three phases: elimination, equilibrium, and 
escape. The elimination phase was the classic “immuno-surveillance”. The equilibrium phase 
was the attempt to maintain the tumor, by further genetic mutation or accumulation, making the 
tumor more resistant to immune attack. Tumor antigens were first established in transplantation. 
Mice, transplanted with tumor cells from other species, were identified with antibodies to 
antigens that were shared by the same type of tumors (Gross 1943; Prehn and Main 1957; Klein 
et al. 1960). Various types of tumor-associated antigens (TAAs) were discovered and classified 
as follows: mutated tumor suppressor gene product (p53); abnormal expression of oncogene 
(HER2/neu); antigens of oncogenic viruses (EBV, HPV); antigen of oncofetal gene production 
(CEA, AFP); differentiation antigens (gp100, MART-1) and others (Tuting et al. 1997; Abbas et 
al. 2000; Renkvist et al. 2001; Davis et al. 2003; Novellino et al. 2005). 
There are various mechanisms that might induce tumor tolerance, leading to the growth, and 
spreading of the tumor, and eventually the death of the host.  
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i. Loss of antigen 
Recent studies on the effect of DNA vaccines, encoding a suicide gene demonstrated 
that the DNA vaccine could reject most melanoma cells; later the tumor broke 
through the therapy and expressed a different phenotype by losing the expression of 
tumor associated antigen (Sanchez-Perez et al. 2005). Losses of melanoma-associated 
antigens, i.e. MART-1, MAGE-3, gp100, was also reported in clinical trials (Khong 
et al. 2004; Riker et al. 1999; Gajewski et al. 2001).  
ii. Loss of MHC  
Weak presentation of antigens by MHC loss in tumors is another mechanism to avoid 
immune destruction. Minimal presentation of antigens can be induced by: a mutation 
or defect in the expression of β2-microglobin of the MHC-I molecule or a defect in 
TAP-1 or TAP-2 (Hicklin et al. 1998; Wang et al. 1999; Seliger et al. 1996; Vitale M 
et al. 1998).  
iii. Lack of co-stimulatory signal and induction of regulatory T cell 
Lack of MHC-II molecules or co-stimulatory molecules on tumor cells may induce 
suppressive regulatory CD4+ T cells which play an important role in inhibiting 
autotumor immunity (Sakaguchi et al. 1995; Shimizu et al. 1999; Sakaguchi et al. 
2001). 
Natural Treg cell in peripheral tissues may suppress immune responses to tumors in a 
non-antigen-specific manner (Bluestone and Abbas 2003; Cozzo et al. 2003). 
Exprimental evidence from mouse models and cancer patients has demonstrated that 
deletion of Tr can enhance antitumor immunity (Liyanage et al. 2002; Curiel et al. 
2004). 
iv. Suppressor products from tumors 
Transforming growth factor (TGF-β) is secreted in large quantities by tumor cells. It 
inhibits the proliferation of effector lymphocytes and macrophages, thereafter, 
enhancing tumor growth. Antigen masking by secretion of glycocalyx molecules by 
tumor cells may also depress antigen-presentation (Alroy et al. 1982).  
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1.3     HER2/neu positive breast cancer 
1.3.1   HER2/neu biology 
1.3.1.1   HER2 and HER family 
Human Epidermal Growth Factor Receptor 2 (HER2), also known as c-erbB-2 and CD340 
(cluster of differentiation 340), is a cell membrane surface-bound receptor tyrosine kinase, which 
belongs to the epidermal growth gactor receptor family (HER/EGFR family). The other three 
members of the HER family (HER1/ EGFR-1, HER3/ EGFR-3, HER4/ EGFR-4), have also been 
identified and function as receptor tyrosine kinases (RTKs). All HER/EGFR families contain an 
extracellular ligand-binding domain (ECD), a trans-membrane domain (TM), and an intracellular 
domain (ICD), which consists of a highly conserved tyrosine kinase domain and a cytoplasmic 
tail. The cytoplasmic tail contains a specific binding motif for a src-homology domain (SH2) 
(Albanell et al. 1999; Slichenmyer et al. 2001), which interacts with many signaling molecules 
and result in changes of gene expression, and triggering of biological functions (Gullick et al. 
2001). 
The first receptor tyrosine kinase identified was the 170 kDa protein HER1. It is the cellular 
homologue of the retroviral avian erythroblastosis tumor gene, v-erbB and is commonly over-
expressed in human cancers (Cohen and Taylor 1974; Downward et al. 1984; Kim et al. 2001; 
Harari 2004; ROSS et al. 2003). The known ligands that bind to it are transforming growth 
factor-α (TGF-α), amphiregulin, heparin-binding EGF-like growth factor (HB-EGF), betacellulin 
and epiregulin (Rubin and Yarden 2001).  
HER-3, also known as c-erbB3, is a 160 kDa receptor. It is the only family member that lacks 
tyrosine kinase activity (Guy et al. 1994) and is therefore unable to direct cell signaling (Kim et 
al. 1998). However, it can be a partner of other EGF receptor family members to form 
heterodimers that lead to activation of pathways in cell proliferation or differentiation. The 
known ligands which bind to it are heregulins and neu-differentiation factors, which are also 
known as neuregulins (Hellyer et al. 2001; Carraway et al.1997; Horan et al1995; Singer et al. 
2001; Rubin and Yarden 2001).  
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HER-4, also known as c-erbB4, is a 180 kDa protein that has four different isoforms depending 
on how it is spliced (Plowman et al. 1993; Zimonjic et al. 1995; Junttila et al. 2000). Ligands 
include neuregulins, heparin-binding EGF-like growth factor and betacellulin. Bindings of 
ligands activate a variety of signals leading to mitogenesis and differentiation. Mutations and/or 
over-expression of HER-4 are associated with various tumors and linked to schizophrenia (Sardi 
et al. 2006; Garcia et al. 2000; Huang et al. 2000). 
1.3.1.2   HER2 and neu 
HER2 is a self-glycoprotein, with the molecular weight of 185 kDa, consisting of 1255 aa, and 
encoded by a proto-oncogene, her2; it is a located on the long arm of human chromosome 17q21 
(Coussens et al. 1985). Like the other three members of the EGFR family, HER2 is composed of 
a cysteine rich extracellular domain (ECD) with four sub-domains consisting of two cysteine rich 
domains and the signal sequence, a single trans-membrane (TM) domain, followed by a 
cytoplasmic tyrosine kinase intracellular domain (ICD) (Yarden et al. 2001; Olayioye MA 2001; 
Slichenmyer, 2001). The extracellular domain is encoded by 632 aa, with 22 aa for the trans-
membrane domain and the remaining 580 aa for the intracellular domain (ICD) (Yarden et al. 
2001). HER2 is unique, and thought to be an orphan receptor as it has no known ligands. 
However, it is the preferential dimerisation partner of the other HER/ErbB family receptors, and 
involved with several signal transduction pathways: 1) the Ras/mitogen-activated protein kinase 
pathway, 2) the PI3K/Akt pathway; 3) the Janus kinase/signal transducer and activator of the 
transcription pathway; and, 4) the PLC-γ pathway, leading to proliferation, differentiation, 
migration and apoptosis (Yarden 2001; Yarden and Sliwkowski 2001; ROSS et al. 2003).  
HER2 is associated with the rat neuroblastoma (neu), based on >85% similarities in nucleic acid 
and amino acid sequences (Yamamoto et al. 1986, King et al. 1985; Semba et al. 1985). The neu 
protein is also a trans-membrane molecule with a molecular weight of 185 kDa, consisting of 
1260 aa. It was first found in rat neuroblastomas and glioblastomas, subsequently termed neu, 
and is involved in the transformatiion of tumorigenic cells (Padhy et al. 1982; Drebin et al. 1984; 
Schechter et al. 1984). Transfection of NIH/3T3 fibroblasts with mutant neu, where valine acid 
(V) is replaced with glutamic acid (E) at aa residue 664 (V664E), induced neoplastic 
transformation (Bargmann et al. 1986Padhy et al.1982; Drebin et al.1986; Yu et al. 1992). In 
vitro studies showed that down-regulation of this gene expression product by using specific 
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monoclonal antibodies can reduce the malignant phenotype of transfected NIH/3T3 cells and 
inhibit cell growth (Drebin et al.1985).  
1.3.1.3   HER family and signaling pathway 
The activation of HER to start cell signaling usually requires both its ligand and another member 
of HER family to form a more stable homodimer or heterodimer compared to a monomeric 
receptor complex (Akiyama et al. 1988; Kokai et al. 1989; Alroy and Yarden 1997;Connelly and 
Stern 1990). Ligand like neuregulin-1 (NRG-1) usually has two binding sites for HER receptors, 
a high-affinity but narrow-specificity site (N-terminal) and a low-affinity but broad-specificity 
site (C-terminal) (Tzahar et al. 1997). The high-affinity site usually binds to HER1, HER3 and 
HER4, while the low-affinity site binds to HER2 (Yarden 2001). With different ligand binding, 
ten different receptor dimers, either homodimers or heterodimers, can be formed by two of the 
four different receptors. Thereafter, the dimers can interact with intracellular substrates, leading 
to signal transduction pathways involved in cell growth, proliferation, differentiation, migration 
and apoptosis. 
After ligand-binding and dimerization, auto-phosphorylations of tyrosine residues in the kinase 
domains occurs, the result is recruitment of signal transducers and activators with binding motifs. 
The binding motifs recognize phosphorylated tyrosines at carboxy-terminal and phosphotyrosine 
binding domains (PTBs), such as the adaptor proteins Grb2, Grb7, Shc, Crk, and Gab1, and lipid 
kinases, which interact with intracellular substrates (Sudol et al.1998; Biscardi et al. 1999; Stover 
et al.1995). Consequently, the various downstream signal transduction molecules, such as Src 
and phosphatidylinositol 3-kinase, phospholipase Cγ, and protein phosphatases, are activated 
which then activate the Ras- activated, Shc-activated, mitogen-activated protein kinase (MAPK), 
the PI(3)K-activated Akt and c-Jun N-terminal kinases (JUNK) pathways for cell proliferation 
(Tzahar and Yarden 1998; Yarden and Sliwkowski 2001; Prenzel et al. 2001; Baxevanis et al. 
2004).  It is interesting to note that HER1 is the only member to which the ubiquitin ligase Cbl 
binds (Levkowitz et al. 1996). HER3 is the one member out of the four, which efficiently 
induces phosphatidylinositol 3-kinase due to its multiple coupling sites for its regulatory subunit 
p85 (Jones, J. et al. 1999). In addition, a PDZ domain-containing protein PSD-95 (Postsynaptic 
Density Protein), known to function in receptor scaffolding, can interact with ErbB4 at neuronal 
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synapses, leading to the enhancement of neuregulin (NRG)-induced kinase activity (Garcia et al. 
2000; Huang et al. 2000). 
The hierarchical network formed by heterodimers, allows for cross-talk regarding intracellular 
signaling to initiate developmental events (Yu and Hung 2000). According to this network, the 
absence of HER2-specific ligands makes HER2 not only work for both ligand-dependent and 
ligand-independent dimers but may also make it a possible coordinator of the entire HER 
signaling network (Yarden 2001). A common partner for HER2 is HER3 that has high affinity 
for its ligands but lacks kinase activity. When cells grow normally, HER2 containing 
heterodimers are at a minimal level and the subsequent signaling activation is weak (Baxevanis 
et al. 2004). When a heterodimer is formed containing HER2, the dimer would possess a higher 
potent signal transduction capability compared to one without HER2 (Graus-Porta et al. 1997; 
Rubin and Yarden 2001). Therefore, over-expression of HER2 may be important in cancers. 
1.3.1.4   HER2 in development 
The HER family plays an important role in cell growth and differentiation, and is expressed 
throughout embryonic development. HER2 is the most widely expressed but at low levels: 
expression is detected in the central nervous system, developing bone, gastrointestinal tract, lung, 
breast, pancreas, ovary, skin, and genitourinary tracts in human fetuses, as well as adult tissues 
(Coussens et al.1985; Quirke et al. 1989; Press et al. 1990; Olayioye et al. 2000). The importance 
of HER2 in embryonic development was discovered in HER2 knockout mice. If HER2 is absent 
during mouse embryonic development, fetus die in the uterus by E11 (embryonic day 11). Death 
resulted from lack of HER2/HER4 binding to the ligand neuregulin-1 which is required for 
formation of myocardium; this in turn, causes trabeculae malformation in heart, and nervous 
system deficiencies as well (Lee et al. 1995; Morris et al. 1999; Meyer and Birchmeyer 1995). 
HER2/neu after birth is involved in normal breast development and growth (Di Augustineand 
Richards 1997; Jones et al. 1996; Normanno and Ciardiello 1997; Yang et al. 1995).  
1.3.2   HER2 and breast cancer  
1.3.2.1   The epidemic of breast cancer  
Breast cancer is currently the most common cancer in women comprising 22.9% of invasive 
cancers in women (World Cancer Report. International Agency for Research on Cancer 2008); it 
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accounts for 16% of all female cancers. In Western countries it is the leading cause of cancer-
related deaths. In Canada, 21,800 women are diagnosed with the disease each year, and 1 in 27 
women will die from it (Canadian Cancer Society, 2006). Breast cancer is strongly age-related. 
With 5% of all breast cancers in women under 40 years old, and it is considerably more 
aggressive when occurring in young women (Sariego 2010). Risk factors of breast cancer include 
hormone levels (Yager and Davidson 2006), race, hereditary history, economic status and dietary 
iodine deficiency (Stoddard et al. 2008). Breast cancer can also occur in men, usually in an 
invasive form (Giordano. 2004). 
1.3.2.2   Treatment of breast cancer 
Treatments for breast cancer include surgery, radiation, hormone therapy, chemotherapy and 
anti-HER2/neu targeted therapy. Surgery is the physical removal of the tumor. Drugs can be used 
afterwards as an adjuvant therapy or can be used prior to surgery. Hormone blocking therapy can 
be a long-term treatment in hormone-positive cancer patients, after testing the levels of estrogen 
and progesterone receptor (ASCO 1998). In many cases, especially in advanced diseases like 
metastatic breast cancer, cancer does not respond to the conventional treatments listed above. 
Hormone therapy, chemotherapy and antibody therapy are combined in the treatment of 
metastatic breast cancer, which is advanced disease that remains incurable with a limited time of 
survival. There are toxic effects, such as drug-induced apoptosis in normal tissues when 
treatments are combined, with limited outcomes (Li et al.1994; Mesner et al.1997; Ozoren et 
al.2003; Kaufmann and Earnshaw. 2000).  Therefore, there is urgent need for novel therapies that 
can be more specific and effective but less toxic for this devastating condition. 
1.3.2.3   HER2 in Breast cancer  
The HER2 gene is expressed only at low levels in normal adult tissues (Press 1990) but at high 
levels in malignances. Of all breast cancers cases, approximately 25~30% have an amplification 
of the HER2 gene or over-expression of its protein product (McCann et al. 1991; van de Vijver et 
al. 1987) and is associated with a high recurrence rate (Slamon et al.1987; Slamon et al. 1989; 
Gusterson et al.1992; Hynes and Stern 1994). Methods to detect and measure the HER2/neu 
status in clinical breast cancer samples can be either morphology-based or molecular-based, 
including matrix-blotting techniques, such as Southern, Northern or Western to detect the DNA, 
RNA and protein status.  
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The chromogenic in situ hybridization (CISH) technique and fluorescence in situ hybridization 
(FISH) are the predominant methods utilized and have been approved by the US Food and Drug 
Administration (Ventana INFORMTM, Abbott-Vysis Path VysisTM) (Ross et al. 2003; Ross et 
al.1998; Press et al. 1997). Since most CISH assays are semiquantitative due to the broad 
distribution of HER2/neu in all epithelial cells, it is necessary to establish a meaningful 
relationship between the number of HER2 receptors and the interpretation of the HER2/neu 
immunostain. The scoring system from studies on cell lines showed that when the receptor 
number was under 20,000 per cell, no stain would show; partial stain (~10% of the cells) 
occurred with 100,000 receptor; light to moderate stain ocurred with 500,000; and strongly 
stained appeared with 2,000,000 receptors (Ross et al. 2003). On the surface of normal breast 
cells, there are only 20-50,000 HER2/neu receptors, whereas, on tumor cells, there were two 
million receptors (Lohrisch and Piccart 2001). 
Gene amplification and the overexpression of HER2 also occurred frequently in other 
malignances, including ovarian cancer (Berchuck et al. 1990; Slamon et al.1989), endometrial 
cancer (Berchuck et al.1991), non-small-cell lung cancer (Kern et al. 1990), gastric cancer (Park 
et al.1989;Yokota et al.1988; Yonemura et al.1991), bladder cancer (Zhau et al.1990), prostate 
cancer (Zhau et al.1992), renal cancer (Herrera 1991) and pancreas cancer (Yamanaka et al. 
1993; Lei et al. Piccart 2001). 
1.3.2.4   HER2 for prognosis, predictive factor and immunotherapeutic target 
A prognostic factor “is one that provides information regarding patient outcome at the time of 
diagnosis”. A predictive factor “is one that provides information regarding the likelihood of 
response to a given therapeutic modality” (Schnitt 2001). The outcome of a prognosis is the 
prediction of the probability of progression-free survival (PFS) or disease-free survival (DFS), as 
associated with the potential of the growth of a tumor and/or its metastases. The outcome of a 
predictive factor is the sensitivity expected to a certain therapy (Kaptain et al. 2001). 
Slamon’s group examined the relativity of overexpression of HER2 to the survival of patients 
compared to those with normal HER2 expression. The accepted results are that HER2 
overexpression has a poor prognosis (Slamon et al. 1987; Ross and Fletcher 1999; Ross et al. 
2003). The utility of HER2 overexpression as a predictive factor for response to theraphy 
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suggests that HER2 results in resistance to hormonal therapy and some types of cytotoxic 
chemotherapy (Ross and Fletcher 1999; Ross et al. 2003), which is beneficial in predicting the 
therapeutic response to breast cancer treatment. No definitive conclusion should be drawn 
because the interpretations of the data available are complex. 
Beyond the clinical utility of HER2 to guide the selection and management of treatment, HER2 
is also an ideal target for specific-anticancer therapy, since it is amplified and overexpressed in 
many human malignancies and it serves as a tumor maker. There are three reasons for HER2/neu 
to be an ideal therapeutic target in breast cancer:  
1.  HER2 is expressed at a high level in 30% of invasive breast cancer, but at low levels of 
normal tissues.  
2. The role of HER2 in the signaling network indicates that it is important in the growth of breast 
cancer and in the development of new anticancer therapies, targeting the HER2 receptor (Yarden 
2001; Yarden and Sliwkowski 2001).  
3. Both humoral and cellular immune responses against the self-protein HER2/neu have been 
observed without any sign or indications of autoimmunity in breast cancer patients (Disis et al. 
1994; Disis et al. 1997; Disis et al. 2000). The anti- HER2 monoclonal antibody (MAb) has been 
developed, approved (Herceptin(R) (trastuzumab) by the US Food and Drug Administration 
(FDA) and used in clinical breast cancer cases. The MAb can improve disease-free survival of 
median stage HER2 positive breast cancers (Jahanzeb 2008; Clifford 2007).  
Although clinical results show that the immune responses are not strong enough to eliminate the 
tumors, HER2/neu specific T-cells have been identified in HER2/neu positive patients, 
indicating a portion of the T cell repertoire is able to recognize the self Ag (Fisk et al. 1995; 
Peoples et al. 1995), with the possibility of finding a novel approach to circumventing the 
tolerance problem.  These factors combined may make HER2/neu a suitable target in developing 
novel immunotherapies, whether passive or active, for HER2/neu positive breast cancer.  
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1.3.3    Investigations into HER2-targeted immunotherapies  
1.3.3.1   Monoclonal antibody targeting HER2  
There are two classes of therapeutic agents targeting HER2 in clinical practice today 
(Mendelsohn 2003); one is monoclonal antibodies (MAbs) that bind the ECD of HER2, thereby 
affecting the dimerization of HER2; the others class tyrosine kinase inhibitors (TKI), which 
block phosphorylation and activation, and thus prevent subsequent downstream signaling events. 
Trastuzumab, or hercepin, is a recombinant, humanized MAb, developed by Genentech Inc. (San 
Francisco, CA) that contains 95% human sequences with only 5% remaining murine sequences 
(Carter et al. 1992). It was approved by the Federal Drug Administration (FDA) in 1998 and 
used in clinical treatments for metastatic and early breast cancers.  Preclinical studies in vitro and 
in animal models found that such MAbs bind to the HER2 in a way that does not harm the 
homodimerization or heterodimerization with other members of the HER family. The anti-
proliferative effects are associated with blockage of the G1 phase of the cell cycle which is 
associated with antiangiogenic effect and antibody-dependent cellular cytotoxicity (ADCC) 
(Nahta et al. 2003; Clynes et al. 2000). Other antibody studies targeting the HER2 signaling 
pathway are ongoing, with some already in clinical trials, such as pertuzumab, a fully humanized 
MAb targeting a different epitope of the ECD of HER2, also known as HER dimerization 
inhibitor (Baselga et al. 2002). 
Clinical studies found MAbs favorable in treatment of the early stage of breast cancer, but with a 
low response rate (Vogel et al. 2002; Cobleigh et al. 1999). However, there were also serious 
adverse events, especially cardiotoxicity and hypersensitivity reactions, in patients with such 
treatment. Therefore, it should be administrated as a combination therapy with other treatments, 
such as chemotherapy, to increase response rate and survival length for advanced breast cancer 
patients with less side effects (Esteva et al. 2002; Fountzilas et al. 2001; Burstein et al. 2003; 
Robert et al. 2006; Chia et al. 2006; Perez et al. 2005; Pegram et al. 2007). There are also, other 
drawbacks. First, MAb resistance eventually develops in cancer patients under MAb treatment, 
which might be due to a lack of trastuzumab-binding extracellular domain. An example is MAb 
resistance occurs if truncated HER2 lack the ECD but retaining its kinase activity (Molina et 
al.2002; Nagy et al. 2005). It was also found that MUC4, a membrane-associated mucin, was 
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correlated with resistance and indirectly correlated with the binding of trastuzumab; it did so by 
masking membrane proteins, such as HER2. Secondly, the strategy and schedule of trastuzumab 
administration is in question, due to its short half-life in patients and the risk factors in the patient 
population, such as advanced age, preexisting cardiac disease or hypertension (Suter et al. 2004). 
Combining MAb treatment with chemokines, peptide vaccines, or DC vaccines may have 
potential clinical utilities. Trastuzumab plus taxanes, produced by plants of the genus Taxus 
(yews), were found to induce recruitment of natural killer cells to tumor sites (Arnould et al. 
2006). Furthermore, trastuzumab plus paclitaxel were found to enhance endogenous humoral and 
cellular anti-HER2 responses, which were associated with favorable clinical outcomes in patients 
with advanced breast cancer (Taylor et al. 2007). Also, HER2 peptide-vaccinated patients 
became sensitive to the effects of trastuzumab on autologous breast tumor cells (Mittendorf et al. 
2006). Recently anti- HER2 antibody treatment combined with an AdVHER-2 vaccine was capable 
of curing 4 out of 10 mice bearing well-established Tg1-1 breast tumors, and significantly 
delayed the death of the remaining 4 tumor-bearing mice (Chen et al. 2011).  Taken together, a 
combination MAb treatment with other therapies may be used as a new therapeutic strategy for 
advanced HER2 -positive breast cancer. 
1.3.3.2   HER2/neu-targeted immunotherapeutic strategies  
1.3.3.2.1   Tumor cell based vaccine 
Autologous or allogeneic whole-cell based tumor cell vaccines have been studied for decades. 
The hypothesis is that tumor cells express many tumor-associated antigens (TAAs) and thus 
present multiple tumor Ags, which may induce sufficient innate immunity as well as adaptive 
immunity to generate antitumor immunity. However, the tumor cell based vaccines tend to be 
less immunogenic.  
The induction of antigen-specific immune responses depends on the presence of co-stimulatory 
signals provided by APCs. Therefore, most solid tumors are unable to provide all the signals 
necessary for T-cell activation since they do not express the co-stimulatory molecules. 
Autologous or allogeneic tumor cell vaccines need to be used in combination with strong 
adjuvants (i.e. BCG (Bacillus Calmette-Guérin); influenza virus) (Wiseman et al. 1995; Ahlert et 
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al. 1997), cytokines (i.e.: GM-CSF, IL-12) (Mach and Dranoff, 2000) or fused dendritic cells 
(Avigan et al. 2003) to improve their immunogenicities (Nawrocki et al. 2001).  Thus, co-
stimulatory factors, such as CD80 or cytokines, have been introduced in these vaccines to confer 
an immuno-stimulant potential to tumor cell-based vaccines (Dols et al. 2003a, Dols et al. 
2003b). GM-CSF was the most potent cytokine adjuvant for vaccination (Dranoff et al. 1993). 
Tumor cells, engineered to secrete GM-CSF, reportedly reduce spontaneous tumor development 
in Tg mice if used with cyclophosphamide (Cy) or HER2/neu monoclonal antibody, which 
enhance the induction of neu-specific CD8+ T cells through Fc-mediated activation of dendritic 
cells (Machiels et al. 2001; Wolpoe et al. 2003; Kim et al. 2008).  
Both autologous and allogeneic HER2-positive tumor cells have been used as vaccines to induce 
antitumor immune responses in clinical trials of breast cancer (Jiang et al. 2000). For example, 
clinical trials using SVBR-1 or SKBR-3, stage VI breast cancer cells transfected with GM-CSF 
plus IFN-α or plus cyclophosphamide/ trastuzumab, have been conducted. In these styudies, 
HER2-specific delayed-type hypersensitivity developed in most patients who received vaccine 
alone or with Cy. HER2-specific antibody responses were enhanced by Cy but higher Cy doses 
suppressed immunity (Emens et al. 2009). 
1.3.3.2.2    Protein-based vaccine 
Protein-based vaccines, where entire epitopes of immunogenic proteins are presented with MHC 
class II molecules on APCs through the exogenous pathway, have been studied for decades. Such 
a therapy may stimulate humoral immune responses to an infectious disease. An example of a 
protein-based vaccine that has been developed for clinical use is the protein subunit vaccine 
against Hepatitis B virus. 
With regard to HER2/neu positive breast cancer, whole HER2 protein or the ECD of HER2 may 
induce anti-HER2 immune response although the response is too weak to protect mice after 
tumor challenge (Taylor et al. 1996; Dela Cruz et al. 2003); others have demonstrated that they 
may induce tolerance (Bernards et al. 1987; Disis et al. 1998). Whole HER2 protein or ICD or 
ECD of HER2 protein together with adjuvants or cytokines may induce stronger immune 
responses (Disis et al. 2004b). Nevertheless, the disadvantage of a protein vaccine is the lack of 
CTL responses, which is essential in eliminating of tumor cells. 
 19 
Phase I clinical studies on stage II/III/VI breast cancer patients using HER2 proteins (HER2 
ICD, aa 676–1255), observed T-cell responses specific to HER2 ICD in 89% of immunized 
patients and 82% developed anti-HER2 IgGs. More than 50% of patients maintained cellular 
immunity for 9–12 months after completion of immunizationsin combination with GM-CSF 
injected intradermally once a month for 6 months. Patients who received the highest dose more 
rapidly developed anti- HER2 immunity (Disis et al. 2004b). Another phase I clinical study on 
stage II/III, using dHER2 (HER2 ECD and ICD) showed that Abs specific to HER2 ECD and 
ICD developed after four immunizations (Limentani 2005). However, some years later, another 
group used a protein-based vaccine composed of a truncated HER2 protein (aa 1–146), 
complexed to a delivery system consisting of cholesteryl pullulan nanogels (CHP) to vaccinate 
breast and ovarian cancer patients. Kitano found that the vaccine was well-tolerated and induced 
CD4+ T and/or CD8+ T-cellular responses specific to the truncated HER2 protein (Kitano et al. 
2006). A later study of this vaccine in combination with GM-CSF in patients with HER2 positive 
cancer found that none of them developed Abs which recognized the HER2 antigen expressed in 
its native form at the surface of tumor cells (Kageyama et al. 2008). 
1.3.3.2.3    Peptide-based vaccine 
Compared to a protein-based vaccine, a peptide vaccine is more specific and able to elicit both 
humoral and cellular immune responses according to the MHC type restriction of the epitope 
identified. Peptide vaccines are also small and easy to produce. However, the drawbacks are: 1) 
the requirement of epitope identification; 2) the short half-life in vivo, and 3) the possibility of 
tolerance induction.  
Among the HER2 peptides described, E75 (p369, aa 369-377) has been entered into several 
clinical trials. Completed clinical studies on E75 vaccines, combined with incomplete Freund’s 
adjuvant (IFA) or GM-CSF showed that vaccination induced a specific anti-peptide immune 
response with no associated toxicity (Zaks et al. 1998; Knutson et al.2002; Murray et al.2002); 
this result was correlated with higher disease-free survival and significantly lower recurrence 
rates in node-positive breast cancer patients (Peoples et al. 2008). Some clinical trials with E75 
vaccine, combined with trastuzumab have been completed or are ongoing (Mittendorf et al. 
2006; Benavides et al. 2009; Peoples 2008). Results showed an increase in the specific and 
stronger cytotoxicity of CTLs in patients, which could be explained by a higher internalization 
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and faster recycling rates of HER2 following trastuzumab binding (Mittendorf et al. 2006).  
It is important to note that HER2 expression could down-regulate expression of MHC class I 
antigens, which, in turn, impaires the ability to produce and display MHC class I peptide ligands 
to specific CTLs (Choudhury et al. 2004; Herrmann et al. 2004; Vertuani et al. 2009). Thus, 
designing HER2 targeted vaccines that induce both HER2-specific CTL and antibody responses. 
Preclinical and clinical studies on HER2 multiple-peptide vaccines demonstrated that these 
vaccines induced both HER2/neu specific humoral and cellular immune responses (Keith et al. 
2002; Zaks and Rosenberg 1998; Disis et al. 1999). The humoral response was less important 
than the anti-HER2 cellular response (Disis et al. 2000; Disis et al. 2004a), due to the fact that 
the vaccines were derived from HLA-restricted T epitopes and/or that the vaccine adjuvant (GM-
CSF) promotes predominantly a cellular response of Th1 type, characterized by IFN-γ secretion 
(Knutson et al. 2001). Clinical studies also showed concomitant epitope spreading, which may be 
general for immunotherapy in oncology and/or a benefit in vaccination trials (Butterfield et al. 
2003; Disis et al. 2008).  As for clinical studies on MHC-Class II peptide vaccine, phase I 
clinical trial showed that vaccines, composed of the MHC-II peptide of HER2 (aa 776–779) 
alone (AE36) or fused on the C-terminal part with a sequence of 4 aa (LRMK) (AE37) with or 
without GM-CSF, could interact with MHC-II molecules and increase dose-dependent CD4+ T 
cell responses (Holmes et al. 2008). 
1.3.3.2.4    DNA based Vaccines 
The immune responses against transgene products expressed by DNA plasmids were first 
discovered by Wolff and colleagues (Wolff et al. 1990). They found that direct intramuscular 
(i.m.) inoculation of naked plasmid DNA in mice could induce both transgene specific cellular 
and humoral immune responses. This finding caused a tremendous amount of research interest in 
the use of DNA vaccination in preventing infectious diseases.  
1.3.3.2.4.1     The design of DNA vaccine and its advantage 
Several key elements need to be taken into account in design of DNA vaccine. First, for safety 
reasons, the plasmid DNA should persist in the eukaryotic cell nuclei as a circular non-
replicating episome that does not integrate its DNA into the host’s genome. Secondly, plasmid 
DNA should contain a replication of origin (ori) that allows the plasmid to replicate within 
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bacterial cells, as well as an antibiotic resistance gene to serve as a selective drug marker. 
Thirdly, multiple cloning sites (MCSs) are needed for gene insertion, with an appropriate 
transcription terminator segment. Finally, the promoter, (or a eukaryotic transcription regulatory 
element) located upstream from the gene is needed to allow for gene transcription. 
Cytomegalovirus (CMV) and the simian virus 40 (SV40) promoters are common promoters. 
Elements that stabilize the mRNA transcript, such as polyadenylation sequences, can be used 
downstream of the promoter (Gurunathan et al. 2000). 
Plasmid DNA as a vaccine has many advantages. DNA vaccine is inexpensive, extremely stable, 
easy to produce and easy to purify and store. It can be easily modified to enhance Ag 
immunogenicity by removing or inserting special sequences, such as cytokine genes and co-
stimulatory molecules (Gurunathan et al. 2000; Reyes-Sandoval and Ertl 2001; Haupt et al. 
2002; Donnelly et al. 2005). DNA for vaccines, which persists in host cells, may result in long-
term expression (Wolff et al. 1990, Wolff et al.1992), thus, providing constant Ag for long 
lasting immunity (Reyes-Sandoval and Ertl 2001). The inherent unmethylated CpG motifs within 
DNA plasmid from bacteria can act as an adjuvant or a danger signal (Pardoll 2002), as these 
motifs are members of the pathogen-associated molecular pattern molecules (PAMPs). The 
antigen expressed within the host cell with the appropriate post-translational modifications 
makes it escape from clearance by host neutralizing antibody. Most importantly, the nature of 
DNA vaccines allows for unrestricted MHC presentation of class I and class II epitopes to CD4+ 
Th and CD8+ CTLs, leading to the induction of both cellular and humoral immune responses 
specific for the target Ag. One major disadvantage of DNA vaccines is the potential risk that 
DNA may integrate into the host genome, which could result in disruption of the host genes, 
leading to tumor growth or autoimmunity (Mahon et al. 1998).  
1.3.3.2.4.2     Delivery system and administration route 
The dose of DNA, as well as the efficiency and efficacy of immune responses induced by DNA 
vaccines, depends largely upon the administration route and delivery method.  
High doses of plasmid DNA have the potential to induce high cellular and relatively low 
humoral immune responses to numerous antigens in mice, even in the absence of adjuvant 
(Ulmer et al. 1993; Wang et al. 1993; Tang et al. 1992; Fynan et al. 1993; Cox et al. 1993; Davis 
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et al. 1993; Lu et al. 1995; Robinson et al. 1993; Yankauckas et al. 1993). To generate adequate 
immune responses, DNA for vaccines needs to be transfected into antigen presenting cells 
(APCs) or somatic cells to enhance presentation of transgene-encoded antigens to the responding 
T lymphocytes (Gurunathan et al. 2000; Wolff et al.1990; Lu et al. 1995).  
There are many different delivery systems and immunization routes available for DNA vaccines. 
Viruses, such as modified vaccine virus (MVA), fowlpox, and adenovirus have innate 
transfection capabilities (Bejon et al. 2006). These viruses have been tested for potential use as 
DNA vaccine delivery vehicles to increase DNA transfection. Non-viral methods have also been 
investigated, such as the gene gun (particle bombardment) (Yoshida et al. 2000), liposomes 
(Khatri et al. 2008; Reimer et al. 1999; Ropert et al. 1999), nanoparticle-based approaches 
(Cohen et al. 2000; Mansouri et al. 2004; Roy et al. 1999; Vijayanathan et al. 2002; Torchilin et 
al. 2006) and high-pressure liquid delivery methods (Trimble et al. 2003; O’Hagan et al. 2004). 
Direct intramuscular (i.m.) or intradermal (i.d.) injections of DNA vectors are common routes for 
DNA vaccine delivery. For i.m injection, muscle cells (myocytes) are the major cells that take up 
DNA vectors through phagocytosis or pinocytosis. However, the uptake efficiency is rather low; 
nearly 90% of the DNA degrades, and less than 1% of the remaining DNA enters the nuclei 
(Babiuk et al. 2003). To increase transfection efficiency, small pores in cells are induced by 
electroporation (Banga and Prausnitz 1998; Widera et al. 2000). However, since myocytes 
express low level of MHCI molecules and no MHCII and co-stimulatory molecules, DNA 
vaccination do not efficiently prime T cells (Hohlfeld et al. 1994) and may induce immune 
ignorance.  
Dendritic cells (DCs) play a key role in inducing Ag-specific T cells and not the host myocytes 
when one is vaccinated with DNA (Corr et al. 1996; Iwasaki et al. 1997).  For i.d DNA, DNA 
vectors have been found to preferentially localize in DC areas of the draining lymph node and in 
Langerhan’s cells in the skin (Casares et al. 1997). This was confirmed by utilizing DNA 
labeling technique such as green fluorescent protein (GFP) and fluorescein isothiocyanate 
(FITC) (Condon et al. 1996; Chattergoon et al. 1998; Dupuis et al. 2000).  
1.3.3.2.4.3     Application of DNA vaccine to HER2 breast cancer study 
The first DNA vaccine in mice resulted in cellular immunity against influenza nucleoproteins, 
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and the discovery of immune responses against the gene expression product of the DNA plasmid 
(Ulmer et al. 1993). Thus, the DNA vaccine became attractive for antiviral immunization 
strategies and cancer immunotherapy (Donnelly et al. 1995; Lu et al. 2008).  
A variety of research groups have shown that DNA vaccines expressing full length HER2 or 
partial length (ECD or ICD) of HER2 induces HER2-specific humoral and T cell immune 
responses (Amici et al. 1998, Chen et al. 1998, Piechocki et al. 2001, Pilon et al. 2001). 
However, in general, antitumor immune responses induced by DNA vaccines were not able to 
convey any beneficial therapeutic effects in HER2/neu transgenic (Tg) mice (Amici et al. 1998, 
Foy et al. 2001; Quaglino et al. 2004a; Radkevich-Brown and Jacob et al. 2009). 
To improve immune responses, DNA vaccines were constructed to include GM-CSF sequence 
and performed by i.m. injection via electroporation to enhance transgene expression. These 
vaccines were found to elicit stronger HER2/neu-specific antitumor immunity in mouse models 
(Wei et al. 2005; Jacob et al. 2006; Jacob et al. 2007). A recent study showed that HER2 DNA-
based vaccine in combination with a novel agonist of the Toll-like receptor 9, called immuno-
modulatory oligonucleotide (IMO), stimulated a stronger anti-tumor antibody-dependent cellular 
cytotoxicity (ADCC) (Aurisicchio et al. 2009). The same anti-HER2 DNA-based vaccine was 
investigated by Jacob et al in three different mouse strains. They found that both the amplitude of 
the induced immune response and the vaccine efficacy depended on the genetic background of 
the mice. They also found that depletion of T-regulatory cells (Treg) could result in better anti-
tumor immunity, although  it may exacerbate autoimmunity (Radkevich-Brown et al. 2009). 
Some anti-HER2/neu DNA-based vaccination strategies have entered the clinical phase and now 
are active, such as phase I clinical study on V930 DNA vaccine which encodes HER2 and 
carcinoembryonic antigen (CEA) (Merck & Co., Inc 2006); pNGVL3 plasmid DNA vaccines 
encoding HER2 intracellular domain (Salazar L.G. 2006); both studies will be finished by the 
end of 2012. 
1.3.3.2.5     Viral vector vaccine 
Compared to non-viral DNA vectors, viral vectors possese higher efficiency in transgene 
delivery (Arthur et al. 1997; Dietz and Vuk-Pavlovic 1998; Zhong et al. 1999). There are now 
many viral vectors available for DNA tranfection, including retroviruses, lentiviruses, 
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adenoviruses (AdV), pox virus, herpes virus, influenza virus, and adeno-associated viruses 
(Humrich and Jenne 2003). The most frequently used vectors are the retroviruses, and the 
adenoviruses (Dyer and Herrling 2000).  
1.3.3.2.5.1     Retroviruses 
Retroviruses are RNA viruse, whoes replication requires the enzyme reverse transcripatase. The 
insertion of double stranded DNA may increase the risk of mutagenesis to the host genome. The 
advantages of using retroviral vectors is their transfection efficiency, and the ability to present 
TAA to both MHC class I and II molecules and thus induce both humoral and cellular immunity. 
As autologous units, they may also induce fewer neutralizing antibodies (Reeves et al. 1996; 
Specht et al. 1997).  
There are three types of retroviruses that are used as viral vectors: oncoviruses, such as murine 
leukemia virus (MLV), lentivirus, such as human immunodeficiency virus (HIV), and the foamy 
viruses (Meyer zum Buschenfelde et al. 2000; zum Buschenfelde et al. 2001; Cui et al. 2003; 
Breckpot et al. 2004; He et al. 2005; Kim et al. 2005b; Robbins and Ghivizzani 1998; Humrich 
and Jenne 2003). The moloney murine leukemia viruses (MMLV) have been engineered to be 
replication defective and will induce HER2/neu specific CD8+ CTL and CD4+ Th1 cells (Meyer 
zum Buschenfelde et al. 2000; zum Buschenfelde et al. 2001).  The lentiviruses, such as the 
human immunodeficiency virus (HIV), are used to transduce DC; they easily transduce both 
actively dividing and non-dividing cells and induce strong and long lasting effective protective 
and therapeutic immunities in various model systems (Robbins and Ghivizzani 1998; Humrich 
and Jenne 2003; Cui et al. 2003; Breckpot et al. 2004; He et al. 2005; Kim et al. 2005).  
Although those viral vectors may induce immune responses, there are safety issues, such as virus 
infections and DNA integration. 
1.3.3.2.5.2     Adenovirus vaccine 
1.3.3.2.5.2.1    Adenovirus and its life cycle  
Adenoviral vectors, unlike retroviruses, are a safe vector for in vivo gene delivery since they do 
not integrate into the host genome. They can also efficiently infect and transfer genes into a 
variety of cell types, including dividing and non-divided cells. 
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Adenoviruses were first isolated in 1953 from human tonsils and adenoidal tissue (Rowe et al. 
1953; Hilleman and Werner, 1954), from which the name was derived. Adenoviruses infect 
various species of vertebrates, including humans. Although adenovirus has a tropisom to the 
respiratory epithelium, it can also infect and transfer genes in a variety of cell types: dividing and 
non-dividing cells, macrophages, dendritic cells, myoblasts, endothelial cells, smooth muscle 
cells, fibroblasts and chondrocytes.  
Based on neutralization assays with animal antisera and the biophysical and biochemical criteria, 
there have been 51 serotypes of human adenoviruses described and grouped into six groups to 
date. Among human adenoviruses (HAdV), serotype 5 (HAdV5) and serotype 2 (HAdV2) are 
well-studied, with HAdV5 used as a prototype for generating HAdV vectors because of its low 
pathogenecity. Studies on the structure and the genome of adenovirus are mostly based on HAd5.  
1.3.3.2.5.2.2    Structure and its genome    
 Adenoviruses are medium-sized (90–100 nm), nonenveloped (naked) icosahedral viruses 
composed of a nucleo-capsid and a double-stranded linear DNA genome. The viral capsid is 
composed of three structural proteins: hexon, fibre, and pentose base (Bergelson et al. 1997). 
Hexon is the major component that forms the 20 facets of the icosahedrons, whereas pentose 
forms the 12vertices together with the fibre. Hexon residues are responsible for type specificity. 
The unique "spike" or fiber, associated with each penton base of the capsid, is a trimeric protein 
that allows for virus attachment to the host cell via the binding to coxsackie-adenovirus receptors 
(CARs) located on the surface of the host cell (Bergelson et al. 1997). The head domain 
sequences may explain differences in receptor specificity between serotypes. Although hexons 
and fibres contain most of the epitopes of adenovirus that can be recognized by neutralizing 
antibodies, there are also epitopes on pentoses recognized by some neutralizing antibodies and 
integrins on host cells.  
There are three immunoreactive regions in the pentoses, one is located in the N-terminal domain; 
one overlaps with the fibre-site, and; the other is on both sides of a conserved symmetrical 
arginyl-glycine-aspartic acid (RGD) motif; the RGD motif is involved in internalization of virus 
and helps escape from neutralization via the fibre protein steric hindrance that prevents IgG 
binding to all RGDs. 
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The double-stranded linear DNA genome is around 37 Kbp with a terminal 55 kDa protein 
attached to each of the 5' ends of the linear dsDNA. Each of these featured proteins used as a 
primer in viral replication and ensures the linear genome is adequately replicated (Rekosh et al, 
1977). Its DNA can be transcribed into at least 30 mRNA, which can be classified as early genes 
and late genes. The early genes include E1A, E1B, E2, E3, and E4 involved in cell cycle, viral 
DNA replication, and delayed early transcripts (IX and IVa2), for invasion of adenovirus into 
host cells. Late genes (L1 to L5) express the structural proteins (Shenk, 1996; Shenk 2001). 
Although this virus has a larger genome than other viruses, it is still very simple with its 
replication and survival reliant on the host cell. 
1.3.3.2.5.2.3    Life cycle and immune response to adenovirus  
 
 
Fig. 1-2 Replication of adenovirus. The replication cycle of adenovirus begins with its infection 
into host cell. The viral fiber protein attaches to a cellular receptor, such as coxsackievirus group 
B and adenovirus receptor (CAR). The adenovirus is endocytosed and internalized through the 
interaction between its penton base and integrins. It is then transported to the nuclear pore 
complex and DNA released into the nucleus to initiate a cascade of viral gene expressions.  
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Early and late proteins are produced. These proteins and newly synthesized viral DNA are 
encapsidated into capsid in nucleus to form progeny viruses. Through cell lysis these virons can be 
released and further infect host cells nearby. 
Infection of adenoviruses into host cells is initiated with the attachment of viral fiber proteins to 
cellular receptors, such as coxsackievirus group B and adenovirus receptor (CAR) (Bergelson et 
al. 1997). The adenoviral particle enters the host cell through endocytosis, which is mediated by 
the interaction between the penton bases and integrins. Subsequently, the capsid proteins start to 
disassemble sequentially, allowing the viruses to escape from neutralizationl clearance by the 
host.  The virions are subsequently transported into the nuclear pore complex and release their 
DNA into the nucleus to initiate a cascade of viral gene expressions. Proteins are packaged at 20-
24 hour after infection (Greber et al. 1993). After the viral DNA and capsid proteins are 
assembled and progeny viruses are generated. At 2-3 days post infection, around 10,000 virues 
per cell can be released for infection of new cells.  
Accompanying the infection and replication of the adenovirus are the host immune responses 
against the virus. The first stage of clearance by the innate immune system, independent of the 
transgene, occurs within 24 hours. Internalization and degradation by phagocytes, natural killer 
cells and neutrophils removes 90% of adenovirus (Cartmell et al., 1999; Worgall et al.1997; 
Michou et al. 1997). The remainder is cleared more slowly over the following weeks by the 
second stage of clearance, which creates memory toward the virus. The second phase is 
important for inducing immune responses against the transient transgene expressed product, 
since during this time, the remaining 10% of adenoviruses with transgenes enter host cells to 
express the transgene and present the transgene products to APCs (Yang et al, 1996; Yang et al., 
1994a&b, Yang et al., 1995). In this second phase, the viral structural proteins/transgene 
products are processed and bound to MHC molecules and then presented to helper T cells 
through interactions between protein/peptide-MHCII complexes and T cell receptors (TCRs). 
With the third signals provided by B7-1/B7-2 and CD28/CTLA4, humoral and cellular immunity 
to virion and transgene products is generated. Therefore, the lifetimes of adenoviruses must be 
considered for administration methods so as to overcome the innate and humeral immunity 
against viral vector and increase the expression of the transgene when utilizing adenovirus as a 
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vector. These requirements have led to the development of three generations of adenovirus 
vector systems. 
1.3.3.2.5.2.4    Adenovirus as vaccine vector      
As a vaccine vector, normally, adenovirus can carry up to 1.2 kb of foreign DNA (Bett et 
al.1993). However, insertion of large amount of foreign DNA requires deletion of part of the 
viral genome. 
 
Fig. 1-3 Schematic diagram of adenovirus genome and the first generation of adenoviral 
vector. The genome length is about 36 kb and is divided into 100 m.u.; E1A/E1B, E2A, E2B, 
E3, E4 represent early transcriptional genes; L1-L5 represent the late gene; black boxes at the 
ends of the genome represent the inverted terminal repeats (ITR); arrow above and below the 
central open box indicate the direction of transcription; the deletion locations (E1 and E3) for the 
first generation of vector are indicated in black arrows on the bottom figure. 
For insertion of DNA larger than 2 kb but smaller than 7.5 kb, the adenoviral vectors can be 
used.  In recombinant HAdVs, the early gene E1/E3, involved in replication of the virus is 
deleted (Saito 1985). Application of this generation requires complement cell lines like 293 to 
provide in trans the E1protein, which is more essential in viral replication (Graham et al. 1977). 
The main drawback with this vector vaccine is that the immune responses induced are, first, 
against viral capsid antigens and later against the transiently expressed transgene product. The 
peak responses occur at 3-4 days, and disappear in 1-2 weeks (Cartmell et al. 1999; Worgall et 
al.1997; Michou et al. 1997; Yang et al, 1996; Yang et al. 1994a, b). Long-term expression of 
HAdV5 vector-encoded product was found in lungs or livers of immunodeficient mice. The 
immunogenicity of E1-deleted HAdV5 vectors, as well as its ability to activate immune cells in 
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the innate immune system, indicate that they could be used for vaccine to induce antitumor 
immunity (Zhang 2001).  
The E1-deleted AdHu5 vectors have been used as a vaccine carrier for rabies virus glycoprotein 
termed Adrab.gp or HuAd5rab.gp (Xiang et al.1996). These vectors induce neutralizing 
antibodies, as well as rabies virus-specific CD8+ and CD4+ T cells against rabies virus challenge 
(Xiang et al. 1995; Xiang et al.1996]. E1-deleted HuAd5 vectors have also been studied in 
rodents for protecting against Dengue virus (Jaiswal and Swaminathan 2003), Ebola virus 
(Sullivan et al. 2000; Sullivan 2003), SARS–coronavirus (Gao 2003) and human papillomavirus 
(He et al. 2000; Tobery et al. 2003; Liu et al. 2000). E1-deleted AdHu5 vaccine vectors, 
expressing antigens of HIV-1, have also been developed and some entered clinical trials 
(Fitzgerald et al. 2003; Pinto et al. 2004; Casimiro et al. 2003; Shiver et al. 2002; Lubeck et al. 
1997; Pinto et al. 2003; Cohen et al. 2001). Most of these vaccines protect the host through 
induction of neutralizing antibodies of IgG2a isotype and small amounts of IgG1 against 
transgene product. Since adenoviral vector interventions in humans critically depend on the 
selectivity and efficiency of gene transfer to target tissues, receptor-binding Ad protein, the fiber, 
can be redesigned to enhance the selectiveness and transduction rate (Campbell et al. 2003; 
Belousova et al. 2008).  
Adenoviral vectors, encoding the extracellular domain (ECD) and the transmembrane domain 
(TM) of HER2 (Ad-HER2-ECD-TM) and the full-length of HER2 with mutation to inactivate  
its kinase function (Ad-HER2-ki), have been studied for the assessment of their immunogenicity 
for inducing antitumor immunity, as well as their oncogenicity in both wild-type (WT) and 
HER2-tolerant transgenic mice. Among these adenoviral vaccines, Ad-HER2-ki was the most 
immunogenic, by exhibiting high immunogenicities in WT animals, retaining immunogenicity in 
HER2-transgenic tolerant animals, and showing strong therapeutic efficacy in treatment models 
(Hartman et al. 2010).  For evaluation of the efficacy of AdV vaccine expressing rat ErbB2 
antigen in a therapeutic setting, studies in transgenic BALB-neuT mouse model demonstrated 
that AdV vaccine induced efficient antibody and CD8+ T cell responses against rat ErbB2 
(Cipriani et al. 2008). Compared to DNA vaccine expressing rat p185 neu protein, the adenoviral 
vaccine induced greater Th1-skewed humoral and CD8 T cell-mediated responses than the DNA 
vaccine (Gallo et al. 2006). Numerous studies have demonstrated that adenovirus-human HER2 
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vaccines could induce fully protection in WT mice from breast tumor cell challenge; it prolonged 
lifespans of transgenic mice, but showed less therapeutic effect in both WT and especially 
transgenic mice (Park et al. 2005; Gallo et al. 2006; Triulzi et al. 2010; Hartman et al. 2010; 
Felizardo et al. 2011). 
We have recently demonstrated that AdVHER2/neu vaccine stimulated HER-2/neu-specific CD8+ 
CTL responses, leading to a significant reduction in breast carcinogenesis in transgenic 
FVBneuN mice; it had little therapeutic effect on pre-existing Tg1-1 tumor even at an early stage 
(Chen et al. 2011). In addition, the HER2/neu adenoviral vaccine when combined with 
trastuzumab treatment was capable of curing 4 of 10 mice bearing well-established Tg1-1 breast 
tumors.  
1.3.3.2.6     Dendrtic cell (DC) vaccines 
Cancer vaccines can now induce therapeutic immunity capable of rejecting existing 
malignancies, either well-established or spreading extensively. Conventional vaccines, designed 
to defend against infectious diseases, are known as protective vaccines; effective immunity can 
be generated before infection but not after diseases are established. Therapeutic immunity is not 
easy to generate against existing diseases. However, it is now appealing to develop even more 
powerful vaccine modalities to manipulate the nature of the host’s immune system to overcome 
the difficulty of treating established diseases. 
DCs are considered to be the most powerful and efficient antigen-presenting cells (APCs) and, to 
a large extent, responsible for priming T cell responses (Zinkernagel 1974; Linsley et al. 2002). 
DCs are termed “nature’s adjuvant” in generating effective immune responses (Steinman and 
Dhodapkar 2001; Steinman and Pope 2002). Thus, it is logical to utilize DCs in vaccination 
schemes to achieve stronger antitumor immunity. An understanding of how DCs induce, 
regulate, and maintain T cell immunity is as important as understanding tumor immunology in 
the design of novel cancer vaccines with improved clinical efficacy (Banchereau and Steinman 
1998; Steinman and Banchereau 2007; Melief 2008). 
1.3.3.2.6.1     DC biology 
DCs are found in the skin, spleen, liver and peripheral blood. The term is defined based upon its 
adherent cell type and stellate morphology (Steinman and Cohn 1973). DCs are characterized by 
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cytoplasmic extensions or membrane processes that form dendrites, pseudopods or veils. They 
express high levels of DC marker (CD11c), MHC class I and II molecules, costimulatory molecules 
(CD80, CD86 and CD40), adhesion molecules (CD11b, CD54), and receptors (FCrR, MMR) for 
efficient Ag capture.   
DCs were first discovered by Paul Langerhans in the late 1800s and named Langerhans cells. In 
the following decades, different subsets and functions were studied. There are two major DC 
subsets: 1) the classical DCs (cDCs) or myeloid DCs, and; 2) the plasmacytoid DCs. In human 
skin, Langerhans cells (LCs) reside in the epidermis. CD1a+ DCs and CD14+ DCs, as well as 
macrophages, reside in dermis and belong to cDCs (Zaba et al. 2007; Klechevsky et al. 2008). 
LCs are potent inducers of antigen specific CD8+ T cells (Celluzzi et al. 1997). Whereas, CD14+ 
DCs are potent inducers of humoral immunity (Klechevsky et al. 2008, Caux et al. 1997).  
Plasmacytoid DCs (pDCs) are the key cells, linking innate and adaptive immunity. They can 
circulate in the blood of both adults and neonates (O’Doherty et al. 1994; Sorg et al. 1999) can 
also enter secondary lymphoid tissues including spleen, and Peyer’s patches. pDCs are 
considered the front line a antiviral immunity (Siegal et al. 1999), as they accumulate at 
inflammatory sites  (Eckert and Schmid 1989), and are capable of rapidly producing high 
amounts of type-I IFN in response to viruses (Siegal et al. 1999). 
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Fig. 1-4 The DC life cycle. The DC precursors, circulating in the blood or residing tissues as 
immature DCs, can be activated when encountering pathogens (e.g. viruses); they secret various 
cytokines, such as IFN-γ, which, in turn, activates eosinophils, macrophages (MF) and natural killer 
(NK) cells; such DCs then undergo a maturational process, including up-regulation of MHC 
molecules, co-stimulatory molecules, and adhesions; they then migrate to lymphoid organs after 
antigen capture; in the lymphoid organs, DCs display peptide-MHC, which selects for rare 
circulating antigen-specific lymphocytes, which induces terminal maturation of DCs to allow for 
lymphocyte expansion and differentiation; the activated T lymphocytes migrate to the injured tissue 
site, where cytotoxic T lymophocytes (CTLs) eventually lyse infected cells. B cells, activated by both 
T cells and DCs, mature to become plasma cells and produce antibodies; helper T cells function by 
secreting cytokines, which permit the activation of macrophages, NK cells, eosinophils, cytotoxic T 
cells and B cells. 
DCs in both mice and humans, derive from a common proliferating progenitors found in bone 
marrow; they enter the blood stream before migration to other tissues (Steinman et al. 1999). At 
these sites, they exist as immature DCs, staying highly active in the uptake and processing of 
protein antigens and searching for signals that may trigger their maturation (Sallusto et al. 1995). 
They may receive maturation or “danger” signals, such as pathogen-associated molecular 
patterns (PAMPs), such as lipopolysaccharide (LPS), bacterial DNA, double stranded RNA 
(Pardoll 2002), and toll-like receptors (TLRs) (Pasare and Medzhitov 2005). The DCs then 
undergo the programmed maturational process by lowering antigen uptake capability (Sallusto et 
al. 1995); they also upregulate their expression of MHC molecules to increase the density of 
MHC: peptide complexes (signal 1) (Zinkernagel1974), as well as costimulatory molecules 
(signal 2) and certain homing chemokine receptors for their migration (Sallusto et al. 1998). 
They then enter draining lymphatic vessels and migrate to secondary lymphoid tissues or 
regional lymph nodes (Bancherau, 1998). There, they present antigens and release so-called 
’signal 3’ factors, such as interleukin-12 (IL-12), IFN-γ to lymphocytes. The type of factors 
released depend on how the DCs were activated, leading to induction of immune responses 
(Scott 1993; Ohshima et al. 1997). 
As the most powerful antigen presenting cells, DCs can deliver tumor antigens to T cells and induce 
antitumor immune responses. In the first reported clinical study on follicular B-cell lymphoma 
patients treated with a DC vaccine, there was one complete tumor regression within the four treated 
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patients (Hsu et al. 1996). This finding sparked interesting in the utility of DCs as an attractive and 
novel tool for treatment of malignant diseases. In the following years, DC-based vaccines have been 
frequently reported to stimulate more efficient antitumor immunity compared to peptide and DNA-
based vaccines (Toes et al. 1998; Yang et al. 1999; Bellone et al. 2000).  
 
There are some limitations or handicaps in developing DC-based vaccines:  
(i) DCs for clinical use are required to be autologous, although they comprise only less than 1% 
of circulating immune cells in the peripheral blood.  
(ii) DCs may generate immune tolerance. Therefore, tumor antigens may be taken up by the 
“wrong” type of DCs in the periphery, which might lead to an “unwanted” type of immune 
response.  
(iii) DCs from patients or tumor bearing mice are often impaired and may be anergic (Chaux et al. 
1997; Gabrilovich et al. 1997; Troy et al. 1998). 
Therefore, special efforts should be made to overcome these limitations. 
1.3.3.2.6.2     In vitro DC culture and the DC maturation  
To obtain sufficient numbers of DCs from in vitro DC culture (Pilon-Thomas et al. 2004), 
several methods have been developed to isolate and/or generate DCs: 1) leukapheresis of cells in 
circulating blood; 2) culture technique for murine BM-derived progenitors and human peripheral 
blood CD14+ monocytes (Inaba et al. 1992, Romani et al. 1996, Lutz et al. 1999, Berger and 
Schultz 2003), and; 3) human CD34+ DC progenitors isolated from BM or cord blood (Romani 
et al. 1994, strobl et al. 1997)  
Immature DCs are efficient in antigens uptake. However, they could induce antigen-specific 
tolerance or immune silencing, which is bad for inducing antitumor immunity but good for 
utilization in transplantation, allergy, autoimmune and chronic inflammatory diseases (Jonuleit et 
al. 2000; Dhodapkar et al. 2001).  DC maturation is as important as antigen loading. The details 
are described in the following sections.  
The first reported DC culture system used monocytic DC precursors stimulated with the 
cytokines granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 for over a 
week (Romani et al. 1994). Addition of CD40L to the DC culture resulted in relative maturation 
and greater antitumor immunity in a squamous cell carcinoma mouse model (Labeur et al. 1999); 
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LPS was another stimuli for maturation of DCs in vitro DC cultures (Chen et al. 2001b; de Vries 
et al. 2003).  
DC maturation can induce upregulation of MHC molecules and co-stimulatory molecules 
(CD40, CD54, CD80 and CD86) (Cella et al. 1997). Cytokines, such as Flt-3L, granuloctye-
colony stimulating factor (G-CSF), IL-1α, IL-1β, IL-6, IL-12, MCP-1 (CCL-2), MIP-1α (CCL-
3), MIP-1β (CCL-4), RANTES (CCL-5), TARC (CCL-17), macrophage derived chemokine 
(MDC; CCL-22), MIP-2 (CXCL2) may also be secreted (Chen et al. 2001b).  
1.3.3.2.6.3     The administration route for DC vaccines 
DCs migrate and relocate to lymphoid tissues, where they interact with T cells and induce T cell 
responses. However, only a small portion of vaccinated DCs migrate into regional lymph nodes 
after administration (De Vries et al. 2003). Therefore, a more appropriate administration routes 
are essential to facilitate successful DC migration into regional lymph nodes. 
Different administration routes can influence different DC homing outcomes and induce 
different types of immune responses. For example, DC injected subcutaneously (s.c.) 
preferentially migrated to the draining lymph nodes 24 hours after injection and peaked at 48 
hours but remained detectable for five days (Lappin et al. 1999; Eggert et al. 1999; Okada et al. 
2001a). If DCs were injected intravenously (i.v.), they  preferentially accumulated in the spleen, 
liver and lungs (Lappin et al. 1999). However, compared to i.v. injection, s.c. resulted in greater 
protective immunity against tumor challenge (Okada et al. 2001a). Bedrosian’s group have 
observed that DCs could be guided by ultrasound and enter into lymph nodes distal from sites of 
malignant diseases; this would make DC’s IL-12 directly exert its full effects on T cell activation 
in the lymph nodes, and enhance the vaccine efficiency (Bedrosian et al. 2003). More research 
on the effect of administration routes relative to outcomes needs to be studied for the optimal DC 
immunization. 
1.3.3.2.6.4     DC vaccines loaded with different antigents  
1.3.3.2.6.4.1     DCs loaded with tumor cell lysates 
Tumor cell lysates are easy to obtain by repeated freeze/thaw or sonication of tumor cells. 
Autologous DCs, loaded with tumor cell lysates, avoid the needs for identification of TAAs 
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(Zhou et al. 2002) and individual HLA classification, given that tumors express a wide variety of 
TAAs, as well as undefined TAAs and rare mutations. Necrotic tumor cell lysates could induce 
DC maturation (Sauter et al. 2000). TAAs in lysates could be presented on MHC class I and 
class II molecules by autologous DC, resulting in a far more efficient cross-presentation (Li et al. 
2001a). They could also activate CD4+ helper T cells, which is important for effective antitumor 
immune responses (Toes et al. 1999) and the generation of long term CD8+ T cell memory (Zajac 
et al. 1998). DCs loaded with tumor cell lysates have been utilizated for treatment of skin cancer 
(Nestle et al. 1998) and metastatic fibrosarcoma in children (Geiger et al. 2000).  
However, some disadvantages, due to the nature of tumor lysates, hold back the development of 
tumor lysate-loaded DC vaccines. Thess include: 
(i) There may be insufficient number of autologous tumor cells from some cancer patients. 
(ii) There is the possibility for the induction of autoimmunitiy due to the presentation of non-
tumor-Ags (Gilboa 2001)  
(iii) The profiles of TAAs may have been changed so that they may not be applicable for 
advanced tumors with metastases  
1.3.3.2.6.4.2     DCs  loaded with TAA peptides 
DCs, pulsed with various HER2/neu epiptops, have been used as antitumor vaccines in 
preclinical animal and human clinical trials. Human DCs, pulsed with HER2/neu peptides p63-
71 and p780-788, or mouse DCs, pulsed with HER2 peptides p369-377 (E75), p435-443, p654-
662, and p689-697, induced HER2 peptide-specific CD8+ T cell responses (Shiku et al. 2000. 
Rongcun et al. 1999; Anderson et al. 2000b; Seliger et al. 2000; Baxevanis et al. 2002; Kono et 
al. 2002; Morse et al. 2003; Sotiropoulou et al. 2003a; Sotiropoulou et al. 2003b; Baxevanis et al. 
2006]. Vaccination using HLA-A2 restricted HER-2 peptide (p654-662)-pulsed DCs entered a 
phase I/II trial, where two patients had partial responses and another two patients also developed 
IFN-γ producing CD8+ T cells (Dees et al. 2004). However, DCs pulsed with a recently 
identified H-2Dq restricted-neu peptide showed no protective responses against neu-expressing 
breast cancer in Tg FVBneuN mice (Ercolini et al. 2003). However, specific tumor lysis activity 
was seen in immunized wild-type FVB/NJ mice. In addition, there was another preclinical study 
using a fusion protein, which consisted of HER2 ECD (p58-492) and HIV hemagglutinin (HA) 
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TAT domain. The fusion protein-loaded into DC vaccines induced both CD4+ and CD8+ T 
responses leading to a significantly reduced tumor growth (Viehl et al. 2005). A clinical trial 
with DCs, loaded with a mixture of 6 HLA class I- and II-restricted peptides (i.e., 3 HER2 ECD-
derived peptides and 3 HER2 ICD-derived peptides) showed that immunized patients developed 
peptide-specific immune responses, leading to a significant reduction of tumor cells with HER2 
expression in the biopsies of surgical patients (Czerniecki et al. 2007). Overall, HER2/neu 
peptide-pulsed DC vaccines can generate CTL responses, but are still not adequate for 
therapeutic effect in a clinical setting. 
1.3.3.2.6.4.3     Adenovirus vector-transduced DC vaccine  
Human adenovirus type 5 (HAdV5) vector has been proven to be safe and efficient in gene 
delivery because its genome does not integrate into the host cell’s genome. Therefore, 
adenovirus is one of the most efficient vehicles for delivering transgenes into DCs. The 
disadvantages of using HAdV5 are its transient gene expression and its toxicity when used at 
high dose (Yang et al. 1994, Morral et al. 1997).  
 
Fig. 1-5 Adenovirus-mediated gene transfer to dendritic cells. An adenoviral vector carries a gene 
expression cassette encoding for a tumor–associated antigen, infects a dendritic cell; the antigen can 
be expressed within the DC, which is processed and presented with MHC I to induce cytotoxic T cell 
responses or with MHC II to induce CD4+ T cell and Ab responses. 
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Experimental tumor models have shown that DCs, transfected with HAd5 vector expressing 
tumor antigens, elicited strong antitumor CTL responses (Song et al., 1997; Song et al., 2000; 
Steitz et al., 2001; Tuting et al., 1999; Wan et al., 1997). DCs, which were transfected with 
adenoviral vector carrying full-length neu (AdNeuTK), induced protective antitumor immunity 
against neu-expressing tumor cell challenge in 60% of immunized mice with (Chen et al. 2001). 
DCs, transfected with adenovirus expressing full extracellular domain (ECD amino acids 22–
652), and transmembrane domain (TM, amino acids 653–675) of HER-2, induced HER-2 
specific CTL responses against neu expressing tumors (Ma et al. 2006). DCs, transfected with 
truncated neu expressing AdV, stimulated both neu-specific antibody and CTL responses in 
BALB-neuT mice (Sakai et al. 2004).  Similar HER2/neu antitumor immunities, induced by 
AdVHER2/neu- and/or modified AdVHER2/neu-transduced DC vaccines, were found in other studies 
(Wu et al. 2005; Chong et al. 2005; Ma et al. 2006). For example, DCs transfected with 
AdVHER2/neu-IL12 expressing HER2/neu and IL-12 or co-transfected with  AdVHER2/neu and 
AdVTNF-α expressing HER2/neu and TNF-α, respectively,  demonstrated efficient HER2/neu-
specific CD4+ T cell and CD8+ CTL responses (Chen et al 2001; Chen et al; 2002; Ma et al. 
2006). Preclinical studies of HER2/neu-specific AdV-transfected DC vaccine showed that it 
could delay the onset of spontaneous HER2/neu over-expressing tumor growth in transgenic 
mice (Sakai et al. 2004).  
To date, AdV-transfected DC-based vaccines can induce antitumor CTL responses and antitumor 
immunity in wild-type mice. However, the vaccine-induced CTL responses are not strong 
enough to induce efficient protective or therapeutic antitumor immunity against HER2/neu 
positive breast cancer in rat HER2/neu-gene transgenic (Tg) mice, because of immune tolerance 
towards HER2/neu. Based upon recent studies using adenovirus- and lentivirus-transfected DCs 
in a HER2/neu overexpressing tumor model, it has been demonstrated that not only the target 
antigen but also the virus system may determine the nature and magnitude of DC-stimulated 
antitumor immunity (Felizardo et al. 2011). Although infections of adenovirus and lentivirus did 
not affect DC maturation, both adenovirus- and lentivirus-transfected DCs expressing HER2/neu 
induced strong CTL responses, similarly leading to inhibition of tumor growth in mice. 
However, AdV-transduced DCs expressing HER2/neu elicited significant humoral responses, as 
well as local and systemical CD4+ and CD8+ T cell responses, whereas lentivirus-transfected 
DCs expressing HER2/neu predominantly stimulated IFN-γ-secreting CD4+ T-cell responses, 
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leading to infiltration of CD4+ T cells at the tumor sites (Felizardo et al. 2011). These results 
suggest that adenovirus-transfected DC vaccine may be a promising tool in inducing CTL 
responses against HER2/neu positive breast cancer. 
1.3.3.2.7      Universal T help epitope from tetanus toxin and its potential function in 
breaking self-tolerance  
CD4+ T helper cells play a crucial role in CD8+ CTL priming, expansion, and memory 
development (Ridge et al. 1998; Bennett et al. 1998; Schoenberger et al. 1998; Wang et al. 2003; 
Janssen et al. 2003; Kirberg et al. 1993; Cardin et al. 1996; Bourgeois et al. 2002; Shirai et al. 
1994). It is generally believed that Th dependent CTL responses are essential in antitumor 
immunity. However, precursors of Th cells as well as CTLs with high affinity for self-antigens, 
including tumor Ags, are eliminated in the thymus, leading to immunological tolerance or poor 
tumor Ag-specific immunity derived from tumor Ag-specific vaccines.  
The tetanus toxin epitope, P30 (FNNFTVSFWLRVPKVSASHLE) is a universally immunogenic 
epitope capable of stimulating CD4+ T cell responses (Panina-Bordignon et al. 1989).  To bypass 
self immune tolerance to tumor Ags, insertion of foreign helper epitopes into HER2/neu antigen 
was designed to overcome immune tolerance to HER2/neu by providing exogenous CD4+ T cell 
help to tumor Ag-specific B and CTL responses (Dalum et al. 1997). This approach bypassed 
immune tolerance toward the highly conserved ubiquitin protein (Dalum et al. 1997) and the 
inflammatory cytokine TNF alpha, leading to endogenous production of therapeutic anti-TNF 
alpha Abs (Dalum et al. 1999; Dalum et al. 1996).  It was later demonstrated that HER2/neu 
DNA vaccine containing the potent Th cell epitope P30 induced complete immune protection 
against tumor cell challenge in wild-type mice, but only a partial antitumor protection in Tg 
mice, whereas HER2/neu protein vaccine containing P30 epitope stimulated protective immune 
responses even in Tg mice (Renard et al. 2003). In an OVA model study, a DNA vaccine 
containing P30 could prevent the growth of OVA-expressing tumor in transgenic rat insulin 
promoter (RIP)-mOVA mice (Steinaa et al. 2005) which express a membrane bound truncated 
OVA sequence under the control of RIP in pancreatic islets as well as in the kidney proximal 
tubules and thymus and in the testis of male mice (Kurts et al. 1996), and exhibit deletional 
tolerance toward the OVA265–280 (SIINFEKL, MHC class I epitope of OVA) epitope (Kurts et al. 
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1997). These results indicate that insertion of a single foreign Th epitope P30 in the self Ag 
could break the CD8+ T cell tolerance, and that it is the tolerance in the CD4+ Th cell 
compartment that helps maintaining the CTL tolerance against self Ag in these Tg mice. 
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2  Hypothesis  
The tetanus toxoid Th P30 epitope has been found to be a universal epitope for sensitizing and 
inducing proliferation of CD4+ T cells ex vivo. OVA-P30 peptide vaccine could break CD8 and 
CD4 T cell tolerances against neo-self-antigen OVA, and was able to protect RIPmOVA Tg 
C57BL6 mice from tumor growth, and that HER2/neu-P30 DNA vaccine could protect wt mice 
from tumor challenge, but induce only moderate protection in spontaneous HER2/neu positive 
tumor growth Tg mice. Therefore, we hypothesis OVA or HER2/neu linked with P30 in the form 
of AdV transduced DCs vaccine can stimulate more efficient antigen specific CTL responses.       
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3   Materials and methods 
3.1        Materials 
3.1.1    Reagents 
     All of the chemicals used and listed in Table 3-1 are molecular biology or research grade. 
Antibodies used and listed in Table 3-2 were either FITC, phycoerythrin (PE) or biotin labeled. 
Table 3-1 List of chemicals 
Chemicals Supplier Name  
Acrylamide:bisacrylamide Bio-Rad 
Agar Invitrogen 
Agarose Invitrogen 
Alkaline phosphatase New England Biolab 
Ammonium chloride EM Sciences 
Ammonium persulfate Gibco 
Ampicillin Sigma 
Bacto-tryptone BD 
Bovine insulin Sigma 
Calcium chloride Sigma 
Cesium chloride Sigma 
CFSE Molecular Probes 
Chloroform EM Sciences 
Coomassie Blue Bio-Rad 
DMEM Gibco 
DMSO Sigma 
dNTP mix (dATP, dCTP, dGTP, dTTP) Invitrogen 
EcoRV NEB 
Electroporation cuvette (0.2cm, 0.4 cm gap) Bio-Rad 
EMEM Gibco 
Ethanol EM Sciences 
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Table 3-1 List of chemicals (Continued.) 
Chemicals Supplier Name  
Ethidium bromide Sigma 
FBS Cyclone 
Ficoll-Paque Amersham Biosciences 
Formalin EM Sciences 
Gentamicin Reagent Solution Gibco 
Glutaraldehyde Sigma 
Glutamin Sigma 
Glycerol BDH Inc 
Glycine EM Sciences 
GM-CSF R&D Systems 
HindIII NEB 
High-Fidelity DNA Polymerase Pharmingen 
Hydrochloric acid EM Sciences 
Isopropanol EM Sciences 
GM-CSF R&D Systems 
HindIII NEB 
High-Fidelity DNA Polymerase Pharmingen 
Hydrochloric acid EM Sciences 
Isopropanol EM Sciences 
Kanamycin Invitrogen 
KpnI NEB 
Ligase NEB 
Lysozyme Sigma 
Methanol EM Sciences 
Non-fat dry milk Carnation 
NeuI peptide (PDSLRDLSVF) San Diego, CA 
OVAI peptide (SIINFEKL) University of Calgary 
PEG-8000 Sigma 
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Table 3-1 List of chemicals (Continued.) 
Chemicals Supplier Name  
Pfx DNA polymerase Invitrogen 
Phenol EM Sciences 
Prestained molecular weight protein marker Bio-Rad 
Proteinase K Invitrogen 
RNAse Amersham Biosciences 
RPMI 1640 Gibco 
SDS Sigma/Bio-Rad 
Sodium acetate BDH Inc 
Sodium azide Sigma 
Sodium hydroxide EM Science 
Streptomycin Sigma 
Sucrose BDH Inc 
Sulfuric Acid (H
2
SO
4
) BDH Inc 
T4 DNA ligase USB 
Taq DNA polymerase Invitrogen 
TEMED Gibco 
TRIS EM Science 
Tween 20 Bio-Rad 
Reagent Supplier Name Triton X-100 Sigma 
Trypan Blue Stain Gibco 
Trypsin/EDTA Gibco 
Yeast Extract Difco 
Β-mercaptoethanol Bio-Rad 
λDNA/HindIII marker Invitrogen 
φX174/HaeIII fragment marker Invitrogen 
XbaI NEB 
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Table 3-2 List of Kits 
Commercial Kit  Supplier Name  
Elutip-D columns  Scheicher & Schuell  
Endo-free Giga Kit  Qiagen  
Endo-free Mega Kit  Qiagen  
GenElute Agarose Spin column  Sigma  
Plasmid Mini prep Kit  Qiagen  
Qiaprep Spin Kit  Qiagen  
QIAquick PCR Purification Kit Qiagen 
Quikchange site directed mutagenesis kit  Stratagene  
RNeasy Mini Kit Qiagent 
SuperScript III First-Strand Synthesis for RT-PCR Invitrogen 
 
Table 3-3 List of Antibodies 
Antibody Supplier 
Anti-H-2K
b
/OVAI (pMHC I)  Dr. Germain (NIH, Bethesda, MD)  
Anti-OVA  Dr. Xiang (Saskatoon Cancer Centre)  
Anti-H-2D
q
/neuI (pMHC I) NIH Tetramer Facility 
Anti-neu Dr. Yang (University of Michigan) 
Anti-IFN-γ  Pharmingen  
Anti-mouse CD11c-FITC  Pharmingen  
Anti-mouse CD4-FITC Pharmingen 
Anti-mouse CD4-PE Pharmingen 
Anti-mouse CD40  Pharmingen  
Anti- mouse CD44-Biotin BD Biosciences 
Anti-mouse CD54  Pharmingen  
Anti-mouse CD8-FITC  Beckman-Coulter  
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Table 3-3 List of Antibodies (Continued.) 
Antibody Supplier 
Anti-mouse CD80  Pharmingen  
Anti- mouse CD8-FITC Pharmingen 
Anti- mouse CD8-PE Pharmingen 
Anti-mouse CD86  Pharmingen  
Anti-mouse H-2K
b
 Pharmingen  
Anti-mouse Ia
b
 Pharmingen 
Goat anti-mouse IgG1  Caltag  
Goat anti-mouse IgG2a Caltag 
Goat anti-mouse IgG-FITC Jackson Immuno Research 
Rabbit anti-mouse IgG-FITC Jackson Immuno Research 
Streptavidin-FITC conjugated  Pharmingen  
Streptavidin-PE conjugated  Pharmingen 
Streptavidin-HRP conjugated Jackson Immuno Research 
 
3.1.2    Cell lines 
3.1.2.1 Bacterial cells  
 Bacterial cells used in this project were DH5α Escherichia coli (E. coli) for vector propagation 
of bacterial hosts, and E. coli BJ5183 for homologous recombination leading to formation of 
AdV vectors, respectively. 
For cell growth, bacterial cells were cultured in flasks, containing Lauria-Bertani (LB) broth, 
which consists of 1.0% (w/v) tryptone (Difco), 0.5% (w/v) yeast extract (Difco) and 1.0% (w/v) 
NaCl. Appropriate antibiotic were supplemented to media, such as ampicillin (100 μg/ml) or 
kanamycin (50 μg/ml). Cells were grown at 37ºC in a shaking incubator with a speed of 200 
r/min. 
For inoculation of transformed bacterial colonies, cells were plated onto selective LB-agar plates. 
The plates contained containing 1.5% (w/v) agar in LB broth with appropriate antibiotics, 
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depending on the vector. The plates were incubated upside down in 5% CO2 incubator at 37ºC 
overnight.  
3.1.2.2 Tumor cell lines 
Cell lines, used in this project, were 293-26, 293-39, BL610OVA and Tg1-1. All cell lines were 
cultured in a humidified CO2 incubator at 37°C with a 5% CO2 atmosphere. For cell counting, 
Trypan-Blue (Gibco) was used to stain dead cells, and cells were counted with a 
haemocytometer. 
The two 293 cell lines, 293-26 and 293-39, contain adenoviral E1 genes. They were purchased 
from Microbix (Toronto, ON). 293-39 was used to construct adenovirus DNA for the formation 
of recombinant adenoviruses; 293-26 was used to amplify recombinant adenoviruses. These cells 
were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco), supplemented with 10% 
FBS, 5% glutamin and 30 μg/ml gentamicin solution (Gibco). They were passaged, using 1X 
citric saline solution (10% (w/v) KCl and 4.4% (w/v) sodium citrate). 
BL6-10OVA cell line was the OVA transgene-expressing BL6-10 melanoma cell line. It was 
developed in Dr. Xiang’s lab. This cell line was grown in αMEM, supplemented with 10% FBS, 
0.5mg/ml hygromicin and 30 μg/ml gentamicin solution (Gibco) for OVA model study. 
Tg1-1 cell line is a mouse breast cancer cell line (H-2Kq), derived from a spontaneous breast 
tumor grown in a female FVBneuN transgenic (Tg) mouse (Dr. T. Kipps, University of 
California, San Diego, CA). This cell line was maintained in DMEM (Gibco), supplemented 
with 10% FBS, 5% glutamine and 30 μg/ml gentamicin solution (Gibco). Cells were passaged, 
using Trypsin/ethylenediamine tetracetic acid (EDTA; Gibco) and used for HER2/neu model 
study. 
3.1.3    Animals 
Wild-type C57BL/6, and Tg FVB/neuN mice were used in this project. All animal experiments 
were approved by the University Committee on Animal Care and Supply in accordance with the 
Canadian Council for Animal Care guidelines. C57BL/6 mice were used in the OVA model 
study, while Tg FVB/neuN mice were used in HER2/neu model study.  
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C57BL/6 were obtained from Jackson Laboratories. Tg FVBneuN (H-2Kq) 
[FVB/NTgN(MMTVneu)202Mul] mice were obtained from Du Pont (Wilmington, DE), and 
bred in the College of Health Science Animal Facility. All mice were housed in College of 
Health Science Animal Facility, University of Saskatchewan.  
 
3 .2       Methods 
3.2.1    Molecular biology techniques  
3.2.1.1    DNA techniques 
3.2.1.1.1   PCR 
Amplification and determination of targeted genes were performed by typical polymerase chain 
reaction (PCR) reactions. Before and after construction of recombinant vectors, PCR reactions 
were performed, using 1 μg of template DNA/cDNA in a final volume of 50 μl, containing 20 
mM Tris-HCl (pH 8.0), 20 mM KCl, 1.5 mM MgCl2, 1 mM dNTP mix, 10 ng of each primer and 
2.5 units of high-fidelity Taq polymerase (Invitrogen). A typical cycle consisted of initial DNA 
denaturation at 94ºC for 5 min, followed by 30~35 amplification cycles at 94ºC for 45 sec~3 
min, 56-58ºC for 1 min and 72ºC for 1 minute, followed by final termination for 10 minute at 
72ºC. Water was used as the template to serve as the negative controls.  
After PCR amplification, one-tenth of the reaction sample was used to perform standard agarose 
gel electrophoresis to determine the length of amplified DNA. 
3.2.1.1.2   Restriction enzyme digestion 
All restriction enzymes were provided by New England Biolabs (NEB). Procedures were carried 
out according to the manufacturer’s protocols. 
One microgram of DNA fragments or the DNA vector was digested, using 1 unit of the specified 
enzymes in 1X, the final recommended buffer. The reactions were incubated at 37°C for 1~2 
hours for complete restriction enzyme digestion. In the case of removal of the 5’ terminal 
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phosphate group, calf intestinal alkaline phosphatase (New England Biolabs) was added to the 
reactions for DNA digestion. 
All the reactions were subjected to standard agarose gel electrophoresis to separate different 
DNA fragments. DNA samples without any digestion were served as the negative controls. 
Targeted DNA bands were cut out for further purification by electrophoresis.  
3.2.1.1.3   Ligation 
Ligation of DNA fragments into DNA vectors was performed in a 20 μl reaction buffer, 
containing 10 mM Tris-acetate (pH 7.5), 10 mM magnesium acetate, 50 mM potassium acetate, 
1 mM adenosine triphosphate (ATP), 1-5 unit T4 DNA ligase (USB), 50 ng of vector DNA and 
at least 200 ng of purified DNA fragments. Ligations were performed in waterbath at 16°C 
overnight. 
3.2.1.1.4   Purification of linear DNA fragments 
PCR products were further purified using either PCR clean kits (QIAquick PCR Purification Kit 
from QIAGEN), or phenol: chloroform: isoamyl alcohol extraction. DNA fragments from 
agarose gels were purified using either gel purification kits (GenElute Agarose spin columns 
from Sigma) or phenol: chloroform: isoamyl alcohol extraction.  
3.2.1.1.5   Agarose gel electrophoresis 
Varying agarose concentrations ranging from 0.7% to 1% in TAE buffer [40 mM Tris-acetate, 1 
mM EDTA containing 1 μg/ml ethidium bromide (EtBR; Sigma)], were cast in a GelHorizon 58 
Apparatus; DNA samples were loaded onto these gels with gel loading buffer consiste of 0.042% 
(w/v) bromophenol blue, 6.67% (w/v) sucrose, and λDNA/Hind III and φX174/Hae III fragment 
DNA were used as markers (Invitrogen). Gel electrophoresis was performed in TAE buffer. To 
get gels visualized and documented, a gel documentation system (Bio-Rad) with UV 
illumination was applied. 
3.2.1.1.6   Competent bacterial cell preparation  
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Competent bacterial cells were used in plasmid DNA transformation and amplification (Chan et 
al. 2006, Cohen et al. 1972, Sambrook et al. 1989). Bacterial cells (DH5α or BJ5183) in LB 
medium were grown until mid log-phase with an OD600 reading between 0.4-0.6. The cells were 
then spun down at 8000 rpm. The 5 mL cell pellet was resuspended in 200 μl ice-cold 50 mM 
calcium chloride (CaCl2) in 10 mM Tris-HCl (pH 8.0) for 5 mL cells. Competent bacterial cells 
were stored in 20% glycerol at -80°C in aliquots. 
3.2.1.1.7   Heat shock transformation 
In DNA transformation, 100 μl of competent cells were mixed with plasmid DNA or DNA 
ligation products and kept on ice for 30 min. The sample was heat shocked at 42°C for 90 sec by 
quickly placing the sample into a waterbath. It was then kept on ice for 10 min. Transformed 
bacteria cells were then cultured in 500 μl LB medium at 37°C in a 5% CO2 for 45 minutes. 
Cells were then added onto selective LB-agar plates by the plate streak method to get individual 
bacteria clone, and cultured at 37°C in 5% CO2 incubator for 12-16 hours.  
3.2.1.1.8   Plasmid DNA purification 
To screen positive recombinant colonies after transformation, single isolated colonies were 
selected; for recombinant BJ5183 colonies, a tiny single colony was selected. The colonies were 
further cultured to amplify copies of recombinant plasmid DNA in LB broth, containing selective 
antibiotics overnight. Cells were pelletted the next day and resuspended in 50 mM glucose, 10 
mM EDTA, 25 mM Tris- HCl (pH 8.0), 2 mg/ml lysozyme (Sigma). The cells were then lysed 
with a 200 mM NaOH, 1% sodium dodecyl sulfate (SDS) solution, followed by addition of 3 M 
sodium acetate, pH 5.2-5.5. Chromosomal DNA, cellular protein and debris were precipitated, 
leaving the plasmid DNA in the supernatant. This fraction was extracted twice with phenol: 
chloroform/isoamyl alcohol, followed by DNA precipitation with ethanol precipitation. The 
DNA precipitation was resuspended in Tris EDTA (TE) buffer (pH 8.0), containing 40 μg/ml 
RNAse A. Its concentration was measured by spectrophotometry at standard A260/A280 
readings. Plasmid DNA was visualized on agarose gels. 
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Positive bacterial colonies, cultured overnight in LB broth with appropriate antibiotics were kept 
in a shaking incubator at 37ºC. The sample of cells were treated, using the same solutions 
mentioned above, Plasmid Mini preps Kit (Qiagent) was used for DNA purification. The purified 
DNA was resuspended in sterile, distilled water. Its concentration was determined by 
spectrophotometry at standard A260/A280 readings. Purified DNA was stored at -20ºC and 
ready for transfections.  
3.2.1.1.9   Sequencing 
A 100 ng DNA template per round and 100 μl of 2 pmol/L per primer were sent to the 
sequencing facilities at the Plant Biotechnology Institute of the National Research Council of 
Canada in Saskatoon, Saskatchewan. Sequences were then analyzed through Blast on NCBI.  
3.2.1.2    RNA methods 
RNA was extracted from mammary cells with RNeasy Mini Kit (Qiagent), following the 
procedures provided by the manufacturer. SuperScript III First-Strand Synthesis for RT-PCR 
(Invitrogent) was used to synthesize cDNA, following the procedures provided by the 
manufacturer. Briefly, 5 ng of RNA was firstly mixed with: 1 μl Primer; 1 μl 50 μM 
oligo(dT)20; 1 μl 50 ng/μl random hexamers; 1 μl 10 mM dNTP mix; appropriate volume of 
DEPC-treated water to make a 10 μl reaction system. The reaction samples were incubated at 
65°C for 5 min. The reaction samples were then transferred onto ice for 1 min. Later, they were 
mixed with cDNA Synthesis Mix: 10× RT buffer; 25 mM MgCl2, 0.1 M DTT, RNaseOUT (40 
U/μl). After incubation for 2 min at 42 °C, 1 μl of reverse transcriptase: SuperScript III RT (200 
U/μl), was added and the reaction was continued for 50 min at 42 °C followed by 15 min at 70 
°C. The reaction was stopped by addition of 1 μl of RNase H and incubation at 37 °C for 20 min. 
A control reaction sample for RT-PCR using the forward primer, 5’-CAGGT TGTCT CCTGC 
GACTT-3’, and the reverse primer, 5’-CTTGC TCAGT GTCCT TGCTG-3’, was used to detect 
the level of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
3.2.1.3    Western blot 
Protein expression in mammary cells can be assessed by using Western blots. In general, cell 
proteins were firstly extracted using extraction buffer containing 125 mM Tris, 0.05% SDS and 
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10% β–ME. After centrifugation at 1000 x g for 5 min, the supernatants containing the protein 
samples were collected, and boiled with protein loading buffer, which contains 4% SDS, 20% 
glycerol, 0.12 M Tris pH 6.8, and 10% β-mercaptoethanol (BME), 2% bromophenol blue (BPB) 
(669.96 g/mol). 
The protein samples were then separated on 12% SDS-polyacrylamide gel electrophoresis 
(PAGE). The gel was then cut and transferred onto polyvinylidene difluoride membrane 
(Millipore) and blocked with OYSSEY blocking buffer (LI-COR Biosciences). The blots were 
incubated with a panel of antibodies specific for OVA and β-actin, followed by futher incubation 
with goat-anti-mouse-IRDye™ 680CW. The blot membrane was scaned using ODYSSEY 
densitometer (LI-COR Biosciences). 
3.2.2    Construction of recombinant AdVs 
To construct recombinant adenoviruses, an AdEasy system (He et al. 1998) using the first 
generation of replication-deficient adenoviral vector was used in combination with a 293 cell line 
that expresses the early E1/E3 proteins. The targeted gene was first inserted into the vector 
pShuttle-CMV. The later was then transformed into bacterial cells BJ5183, containing the 
backbone gene of the first generation of adenovirus vector pAdEasy-1. The vectors pShuttle-
CMV and pAdEasy-1 were obtained from AdEasy XL Adenoviral Vector System (Stratagene), 
respectively.  AdVpLpA, containing no transgene, was previously constructed in Dr. Xiang’s lab 
(Wright et al. 1999), and used as a control.  
3.2.2.1   Construction of AdVOVA-P30 and AdVHER2/neu-P30 
P30 was inserted into OVA to form a mutant gene OVA-P30 by replacing IAb epitope OVA265–280 
(TEWTSSNVMEERKIKV) with P30 using Splice Overlap Extension (SOE)-PCR method (refer 
to Fig. 3-1).  
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MGSIGAASME FCFDVFKELK VHHANENIFY CPIAIMSALA MVYLGAKDST RTQINKVVRF 
DKLPGFGDSI EAQCGTSVNV HSSLRDILNQ ITKPNDVYSF SLASRLYAEE RYPILPEYLQ 
CVKELYRGGL EPINFQTAAD QARELINSWV ESQTNGIIRN VLQPSSVDSQ TAMVLVNAIV 
FKGLWEKTFK DEDTQAMPFR VTEQESKPVQ MMYQIGLFRV ASMASEKMKI LELPFASGTM 
SMLVLLPDEV SGLEQLESII NFEKLTEWTS SNVMEERKIK VYLPRMKMEE KYNLTSVLMA 
(aa site 265-280 Replaced by P30 AA: FNNFTVSFWLRVPKVSASHLE) 
MGITDVFSSS ANLSGISSAE SLKISQAVHA AHAEINEAGR EVVGSAEAGV DAASVSEEFR 
       ADHPFLFCIK HIATNAVLFG RCVSP 
Fig. 3-1 P30 insertion site on OVA. The P30 sequence is used to replace the IAb epitope that locates 
at 265–280 aa of OVA protein. 
 
P30 sequence was inserted into HER2/neu gene to form mutant HER2/neu-P30 by replacing the 
IAq epitope HER2/neu781–195 (GVGSPYVSRL LGICL) with P30 using PCR plus 
digestion/ligation method.  
 
MIIMELAAWC RWGFLLALLP PGIAGTQVCT GTDMKLRLPA SPETHLDMLR HLYQGCQVVQ 
GNLELTYVPA NASLSFLQDI QEVQGYMLIA HNQVKRVPLQ RLRIVRGTQL FEDKYALAVL 
DNRDPQDNVA ASTPGRTPEG LRELQLRSLT EILKGGVLIR GNPQLCYQDM VLWKDVFRKN 
NQLAPVDIDT NRSRACPPCA PACKDNHCWG ESPEDCQILT GTICTSGCAR CKGRLPTDCC 
HEQCAAGCTG PKHSDCLACL HFNHSGICEL HCPALVTYNT DTFESMHNPE GRYTFGASCV 
TTCPYNYLST EVGSCTLVCP PNNQEVTAED GTQRCEKCSK PCARVCYGLG MEHLRGARAI 
TSDNVQEFDG CKKIFGSLAF LPESFDGDPS SGIAPLRPEQ LQVFETLEEI TGYLYISAWP 
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DSLRDLSVFQ NLRIIRGRIL HDGAYSLTLQ GLGIHSLGLR SLRELGSGLA LIHRNAHLCF 
VHTVPWDQLF RNPHQALLHS GNRPEEDLCV SSGLVCNSLC AHGHCWGPGP TQCVNCSHFL 
RGQECVEECR VWKGLPREYV SDKRCLPCHP ECQPQNSSET CFGSEADQCA ACAHYKDSSS 
CVARCPSGVK PDLSYMPIWK YPDEEGICQP CPINCTHSCV DLDERGCPAE QRASPVTFII 
ATVEGVLLFL ILVVVVGILI KRRRQKIRKY TMRRLLQETE LVEPLTPSGA MPNQAQMRIL 
KETELRKVKV LGSGAFGTVY KGIWIPDGEN VKIPVAIKVL RENTSPKANK EILDEAYVMA 
GVGSPYVSRL LGICLTSTVQ LVTQLMPYGC LLDHVREHRG RLGSQDLLNW CVQIAKGMSY 
(aa sequence site 781-795 replaced by P30 aa: FNNFTVSFWLRVPKVSASHLE) 
LEDVRLVHRD LAARNVLVKS PNHVKITDFG LARLLDIDET EYHADGGKVP IKWMALESIL 
RRRFTHQSDV WSYGVTVWEL MTFGAKPYDG IPAREIPDLL EKGERLPQPP ICTIDVYMIM 
VKCWMIDSEC RPRFRELVSE FSRMARDPQR FVVIQNEDLG PSSPMDSTFY RSLLEDDDMG 
DLVDAEEYLV PQQGFFSPDP TPGTGSTAHR RHRSSSTRSG GGELTLGLEP SEEGPPRSPL 
APSEGAGSDV FDGDLAMGVT KGLQSLSPHD LSPLQRYSED PTLPLPPETD GYVAPLACSP 
QPEYVNQSEV QPQPPLTPEG PLPPVRPAGA TLERPKTLSP GKNGVVKDVF AFGGAVENPE 
YLVPREGTAS PPHPSPAFSP AFDNLYYWDQ NSSEQGPPPS NFEGTPTAEN PEYLGLDVPV 
Fig. 3-2 P30 insertion site on HER2/neu. TheP30 sequence is used to replace the IAb epitope that 
locates at 265–280 aa of HER2/neu protein. 
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3.2.2.3   Targeted gene insertion into pShuttle-CMV vector 
 
 
Fig. 3-3 Schemtic map of the insertion of target gene. (A) OVA-P30 gene was inserted into the 
pShuttle-CMV vector at the MCS site between BagI and SalI, and (B) HER2/neu-P30 was inserted 
into pShuttle-CMV vector at the MCS site between KpnI and HindIII. 
The OVA-P30 fragment (BagI/SalI digested) was inserted into the pShuttle-CMV vector previously 
digested with BagI/SalI.  Ligation products were then transformed into DH5α host bacterial cells for 
positive selection on LB broth agar plate with 100 μg/ml kanamycin overnight. The pShuttle-CMV-
OVA-P30 DNA was further amplified from DH5α host bacterial cells grown in LB broth with 100 
μg/ml kanamycin, using Plasmid Mini prep Kit (Qiagen). Similar procedures were applied to 
construction of pShuttle-CMV-HER2/neu-P30. 
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3.2.2.4   Overview of scheme of recombinant adenovirus construction  
The formation of recombinant adenoviral vector was achieved in pAdEasy-1-containing BJ5183 
E. coli competent cells by homologous recombination. After the insertion of OVA-P30 into 
pShuttle-CMV, a total of 1 μg of pShuttle-CMV-OVA-P30 was linearized by PmeI digestion. 
This linrized vector was then transformed into BJ5183 E. coli competent cells via heat shock 
transformation (as outlined in Section 3.2.1.1.7) for homologous recombination.  
The transformed cells were then cultured on selective LB-agar plates containing 100 μg/ml 
kanamycin, and inverted overnight at 37°C in a CO2 incubator. To enhance positive selection 
ratio of recombinant adenoviral plasmids, several small colonies were selected and grown in LB 
broth with 100 μg/ml kanamycin overnight at 37°C in a shaking incubator. The plasmid DNA 
was isolated from bacterial cells, using a Mini-preps kit (Qiagen). The plasmid DNA was 
screened for positive selection of the recombinant vector, using restriction enzyme analysis and 
then analyzed on a 0.7% agarose gel. The copy of the resulting positive pAdEasy-OVA-P30 
plasmid was further amplified in DH5α cells. Large amounts of plasmid DNA from DH5α cells 
were then purified using Plasmid Mini kits (Qiagen), and stored at -20°C until use for the 
generation of recombinant adenoviruses.  Purified plasmid pAdEasy-OVA-P30 was then 
linearized by PacI digestion, and then transfected into 293 cells to produce the replication-
deficient recombinant adenovirus AdVOVA-P30 (refer to Fig.3-4). A similar procedure was applied 
for creating AdVHER2/neu-P30. 
 56 
 
Fig. 3-4 Schematic overview of recombinant adenovirus construction, using the AdEasy 
system. The target gene was inserted into the pShuttle-CMV vector before homologous 
recombination with the HuAd5 backbone gene. The vector containing the target gene (pShuttle-
CMV-target gene) was linearized with Pme I restriction enzyme, and then transformed into 
BJ5183 E. coli cells containing the backbone vector, pAdEasy-1. Homologous recombination 
between the two vectors in BJ5183 E. coli cells resulted in adenoviral vector pAdEasy-target 
gene. The recombinant vector was linearized with PacI and then tranfected into 293 cells. 
Adenovirus particals will be generated within host cells and released. 
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3.2.2.5   Generation of recombinant adenoviruses 
To generate recombinant adenoviral plasmid vectors, pAdEasy-target-gene was linearized with  
PacI enzyme. It was tranfected into 293 cells using a liposome-based transfection method. The 
linearized recombinant adenoviral DNA vector (4 μg) was added into 500 μL OPTI-MEM 
medium. Lipofectamine (16 μl) was added into another 500 μL OPTI-MEM medium 
(Invitrogen). Each mixture was incubated at room temperature for 5 min. These two mixtures 
were then further mixed and kept at room temperature for 20 min. The DNA:liposome mixture 
solution was added to 293 cells plated at a cell density of 1x106 cells per 36 cm2 plate. The cells 
were incubated in 2 mL OPTI-MEM medium at 37°C in a CO2 incubator. The medium was 
replaced by DMEM with 10% FCS and 5% Glutamine after 4 hours, and continually monitored 
for 7-10 days by microscopy for formation of plaques. The cell culture medium was refreshed as 
required. When cytopathic effects (CPE) were apparent and extensive, cells with the medium, in 
case of any adenovirus releasing into the cell culture medium, underwent five rounds of 
freeze/thaw cycles performed at -80°C and 37°C, respectively, resulting in generation of the 
initial crude viral lysates. To amplify the crude viral lysates, more T75cm2 flasks of 293 cells 
were infected by the initial crude viral lysates. Infected cells went through further freeze/thaw 
cycles. The cell lysates were then spun down. The supernatants were used as the source of the 
virus for further infection of additional 293 cells. The final amplification step was performed, 
using a total of 36 T175 cm2 flasks. When CPE were apparent and extensive, cells were 
harvested and pelleted. Cell pellets from every 6 flasks were resuspended in 3 mL serum free 
EMEM medium, and were then subjected to five rounds of freeze/thaw cycles for preparation of 
cell lysate samples.  
3.2.2.6   Purification of recombinant adenoviruses  
The cell lysate samples were centrifuged at 10,000 ×g in a JA-17 rotor for one hour. The 
supernatant was gently collected and further purified by density gradient centrifugation. The 
density gradient centrifugation was performed by laying the sample onto the top of a 
discontinuous cesium chloride (CsCl) gradient. The gradient consisted of a layer of 1.25 g/ml 
CsCl, layered gently over the 1.40 g/ml CsCl layer in a Quick-Seal Centrifuge tube for 
ultracentrifugation. Samples were spun in a Beckman ultracentrifuge at 150,000 ×g (~50,000 
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rpm) for two hours, using a Type 80 Ti rotor at 20°C in brake-off mode.  The opalescent band 
close to the bottom was collected with a 25G needle on a 5mL syringe. The band was layed onto 
a 1.34 gm/ml CsCl continuous gradient and spun at 150,000 ×g (~50,000 rpm) for 18 hours at 
20°C. The viral band was carefully aspirated with 25G needle on a 5mL syringe. The sample was 
futher dialyzed to remove CsCl. All CsCl solutions were prepared and autocleaved in 1× TD 
buffer consisting of 140 mM NaCl, 5 mM KCl, 25 mM Tris and 0.7 mM Na2HPO4.  
The samples were injected into a Slide-A-lyzer dialyzing cassette (Pierce) for dialysis using a 
dialysis buffer, containing10 mM Tris-HCl pH 7.4, 1 mM MgCl2 for 4 hours at 4°C. The buffer 
was changed once every hour to remove CsCl. Viruses were collected and the viral concentration 
was measured by a spectrophotometer at A260 with an optical density (O.D.) unit of 1, equivalent 
to1010 plaque forming unit (PFU)/ml (Xiang and Wu 2003).  For viral storage, glycerol was 
added to the purified AdV samples at a final concentration of 10% (v/v) glycerol, then stored at -
80°C. 
3.2.3    Construction of the engineered dendritic cell vaccine  
3.2.3.1   DC culture 
Dendritic cells were generated from bone marrow (BM) culture (Lutz et al. 1999). BM cells were 
taken from femurs and tibias of mice; red blood cells were then depleted with 0.84% ammonium 
chloride. BM cells were plated in Dulbecco's modified Eagle's medium (DMEM) plus 10% FCS, 
GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) on the first day. Non-adherent granulocytes, B and T 
lymphocytes were gently removed on the third day, and fresh media were added. Two days later, 
loosely adherent proliferating DC aggregates were dislodged and replated. On the seventh day, non-
adherent mature DC cells with typical morphologic features of THE DCs were harvested for AdV 
transfection and phenotypic analysis (refer to Fig.3-5). 
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Fig. 3-5 A schematic map of DC vaccine production. Bone marrow was taken out of mice and 
cultured in plates with medium containing cytokines to stimulat DC maturation before 
introduction into DC vaccine via recombinant adenovirus tranfection.  
3.2.3.2   AdV transfection 
On the seventh day, mature DCs were harvested for transfection by recombinant adnenoviruses. 
For optimal transfection, a multiplicity of infection (MOI) of 200 was used per DC, as previously 
described (Chen et al. 2002). To enhance viral adsorption, DCs with virus were cultured in 1 mL 
DMEM in a 6-well culture plate for 1h at 37°C in a 5% CO2 incubator. More DC culture 
medium (4 mL) was added to each well for an additional 24-36 hours. DCs were then harvested 
for phenotypic analysis by flow cytometry. DCs, transfected with AdVOVA, AdVOVA-P30, 
AdVHER2/neu, AdVHER2/neu-P30, were termed DCOVA, DCOVA-P30, DCHER2/neu, and DCHER2/neu-P30, 
respectively.  Engineered DC vaccines were stored at -196°C in liquid nitrogen tank for future 
use.  
3.2.3.3   Flow cytometry analysis 
Transfected DCs were phenotypicaly analysized by flow cytometry. Cells were firstly harvested 
and spun down by centrifugation. After washing twice with PBS, cells (5×106) were then 
incubated with 5 μg/ml biotin-labeled primary Ab for at least 30 mins on ice. Following three 
washes, cells were stained with FITC-avidin for another 30 min. Isotype-matched mAbs were 
used as negative controls. Cells (1×106) were analyzed by flow cytometry (Beckman-Coulter) 
after washing.  
3.2.4    Animal study  
3.2.4.1    Vaccination of Mice 
3.2.4.1.1   Recombinant adenovirus vaccine  
To evaluate CTL responses induced by recombinant adenovirus, AdVOVA, or AdVneu were 
injected (i.v.) into C57BL/6 mice or FVBneuN mice, repectively. In antitumor studies, both the 
(s.c.) and the (i.v.) administration were used, for anti-primary tumor study and anti-metastasic 
tumor studies, respectively. 
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3.2.4.1.2   Engineered DC vaccine  
The same administration routes used for recombinant adenovirus vaccine were also used for the 
engineered DC vaccines when studing induced immune response as well as vaccine effectiveness 
in antitumor immunity studies. However, different doses of the freshly engineered DC vaccines 
were also used. 
3.2.4.2      Assessment of CTL responses 
3.2.4.2.1   Tetramer staining 
C57BL/6 mice were immunized by i.v. injection with either AdVOVA (1×107 PFU), AdVOVA-P30 
(1×107 PFU), DCOVA (5×105), or DCOVA-P30 (5×105). At 11 days after the immunization, 100 µL 
of mouse peripheral blood was stained with FITC-conjugated anti-CD8 Ab and PE-conjugated 
H-2Kb/OVA257–264 tetramer for 30 min at room temperature and analyzed by flow cytometry.  
FVBneuN Tg mice were immunized by i.v. injection with AdVHER2/neu (1×107 PFU) per mouse, 
Eleven days after AdV immunization, 100 µL of mouse peripheral blood was incubated with 
FITC-conjugated anti-CD8 Ab and PE-labeled H-2Dq/HER-2 peptide tetramer for 30 min at 
room temperature and analyzed by flow cytometry. 
3.2.4.2.2   IFN-γ secreting CD8+ T cells 
Tg FVBneuN mice were immunized by i.v. injection of either DCHER2/neu-P30 (5×105), or 
DCHER2/neu (5×105). Six days after DC immunization, 150 µL of mouse peripheral blood was 
collected in heparin solution and lysed with RBC Lysis/Fixation Solution without fixation buffer. 
Cells were then pulsed with 0.5 μL 1.25 mM peptide in 250 μL DMEM.  Five hours later, cells 
were permeated for intra cellular staining using Cytofix/Cytoperm solution following the 
manufacture procedure. Cells were harvested and stained with PE-conjugated-anti-IFN-γ mAb 
for 30 min on ice. After 2× washing, cells were stained with FITC-conjugated-anti-CD8 mAb for 
another 30 min and analyzed by flow cytometry.  
3.2.4.3   Activated T cell detection 
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Activated CD4+ and CD8+ T cells were detected by evaluating CD4+CD44+ and CD8+CD44+ T 
cell with flow cytometry.  
C57BL/6 mice were immunized by i.v. injection of either DCOVA, or DCOVA-P30. It has been 
demonstrated that CD4+ T cells responses reach to the peak amount at day 1 or 2 after DC 
immunization (Ahmed et al. 2012). To detect CD4+ CD44+, two days after immunization, spleen 
cells were collected and stained with anti-CD4-FITC-conjugated antibody and anti-CD44-biotin-
conjugated antibody. After washing 3×, cells were stained with Streptavidin-PE. Cells were 
analyzed by flow cytometry after washing 3×.  
Tg FVBneuN mice were immunized by i.v. injection with either DCHER2/neu-P30, or DCHER2/neu. To 
detect CD44+CD4+ T cells, two days after DC immunization, spleen cells were collected and 
stained with anti-CD4-PE- conjugated antibody and anti-CD44-biotin-conjugated. After 3× 
washing, cells were stained with Strevidin-FITC. Cells were harvested and analyzed by flow 
cytometry after washing 3×.  
To detect CD44+CD8+T cells, six days after DC immunization, 100 µL of mouse peripheral 
blood were collected and stained with anti-CD8-PE- conjugated antibody and anti-CD44-biotin- 
conjugated. Cells were further stained with Strevidin-FITC after washing 3×. Cells were 
analyzed by flow cytometry.  
3.2.4.4    Cytotoxicity assay 
An in vivo cytotoxicity assay was performed in mice 10 days after recombinant adenovirus 
vaccination or 7 days after engineered DC vaccination. Briefly, naïve C57BL6 mouse spleens 
were removed and dispensed into single cells; red blood cells were then lysed with 0.84% 
ammonium chloride.  
Splenocytes pulsed with OVAI peptide were labeled with carboxyl-fluorescein succinimidyl 
ester (CFSE) (3.0 mM, CFSEhigh) and served as OVA-specific target cells, whereas spleen cells 
pulsed with irrelevant Mut1 peptide were weakly labeled with CFSE (0.6 mM, CFSElow) and 
served as nonspecific control target cells. Immunized mice were then i.v. injected with a 1:1 
(CFSEhigh: CFSElow) mixture of splenocyte targets. Sixteen hours after target cell delivery, 
spleens of the recipient mice were removed, and the relative proportions of CFSEhigh and 
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CFSElow target cells remaining in the spleens were analyzed by flow cytometry. 
3.2.4.5    Antitumor immunity study 
Two types of animal studies were conducted. The first type of animal study was performed for 
evaluation of preventative antitumor immunity.  
C57BL/6 mice were s.c. vaccinated with AdVOVA (1×107 PFU per mouse, 10 mice per group). 
Eleven days after the immunization, C57BL/6 mice were s.c. injected in the right thigh with 
BL6-10OVA tumor cells (3×105 cells per mouse). Each mouse was monitored weekly for tumor 
growth measured in two perpendicular diameters using a caliper. Tumor volume (mm3) was 
calculated using the formula V=a×b2/2, where a is the largest and b is the smallest diameter, and 
represented as mean±s.d. Mice with a volume >100 mm3 (or 12 mm in diameters) were 
euthanized for humanitarian reasons. C57BL/6 mice (8 mice per group) were i.v. vaccinated with 
either DCOVA, or DCOVA-P30, and on the seventh day post immunization, BL6-10OVA tumor cells 
(0.3×106 cells per mouse) were injected i.v. into each mouse. Each mouse was monitored weekly 
for 21 days and lungs were then collected for tumor colony counting.  
Tg FVBneuN (10 mice per group) mice at 2 months old were vaccinated s.c. with AdVHER2/neu 
(1×107 PFU per mouse) at 1-month intervals for a total of five vaccinations. Spontaneous breast 
tumor development was monitored weekly for up to 12 months. Tg FVBneuN mice (8 mice per 
group), which are Tg1-1 tumor bearing, were vaccinated i.v. with either DCHER2/neu, or 
DCHER2/neu-P30, and seven days post immunization, Tg1-1 tumor cells (3×105 cells or 1×106 per 
mouse) were injected i.v. into each mouse. Each mouse was monitored weekly for 21 days and 
lungs were collected for analysis for tumor colony counting.  
The second type of animal study was performed to evaluate of the therapeutic antitumor 
immunity. C57BL/6 mice (8 mice per group) were i.v. injected with BL6-10OVA tumor cells 
(0.3×106 cells per mouse). Three days after tumor challenge, each mouse was i.v. vaccinated 
with either DCOVA, or DCOVA-P30. Mice were monitored weekly for 21 days and lungs were then 
collected for analysis for tumor colony counting.  
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3.2.5    Statistics analysis 
Prism software (GraphPad Software, Inc., San Diego, CA) was used for statistical analyses. 
Kaplan-Meier survival chart and Log-rank test were performed to compare mouse survival rates 
and tumor development between different treatment groups. Student T tests were performed to 
determine the significance of differences between groups, and P values less than 0.05 (P<0.05) 
were considered statistically significant. 
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4   Results  
4.1        Part A. Study on adenovirus vaccine in animal models 
4.1.1    Immune response induced by AdVOVA 
To assess CD8+ T cell immune responses, wild-type C57BL/6 mice were immunized i.v. with 
recombinant OVA-expressing adenovirus (AdVOVA). Mouse peripheral blood (100 μL) obtained 
from immunized mice at different days after immunization were stained with FITC-anti-CD8 
antibody and PE-H-2Kb/OVA257-264 tetramer, and analyzed by flow cytometry. C57BL/6 mice 
immunized with PBS or AdVnull were used as negative controls. We found that AdVOVA vaccine 
stimulated  sustained OVA-specific CD8+ T-cell responses, accounting for 18.6% of the total 
CD8+ T-cell population (Fig 4-1); this is significantly larger than 0.07% OVA-specific CD8+ T-
cell responses in mice immunized with the control AdVNull (P<0.01). The OVA-specific CD8+ T-
cell responses peaked on day 11 after the immunization, and then declined slowly (refer to Fig.4-
2). 
 
Fig.4-1 AdVOVA stimulation of ovalbumin (OVA)-specific CD8+ cytotoxic T lymphocyte 
(CTL) responses. Tail blood samples of AdVova-immunized C57BL/6 mice were harvested on 
day 11 after the immunization, stained with PE-H-2Kb/OVAI peptide tetramer and FITC-anti-
CD8 Ab and then analyzed by flow cytometry; values in each panel represent the percentage of 
OVA-specific (tetramer-positive) CD8+ T cells vs the total CD8+ T-cell population; values in 
parenthesis represent standard deviation; student’s t-test (P<0.05) result showed AdVova 
induced higher level of CD8+ CTL than that of AdVnull. One representative experiment of two is 
shown. 
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Fig.4-2 Quantification of OVA-specific CD8+ T cell population at different times. OVA-
specific CD8+ T cell response was induced by AdVOVA after vaccination; mouse tail blood 
samples were harvested on different days after immunization and lymphocytes were stained with 
PE-H-2Kb/ OVAI peptide tetramer and fluorescein isothiocyanate (FITC)-anti-CD8 antibody 
(Ab) and then analyzed by flow cytometry. One representative experiment of two is shown. 
4.1.2    OVA-specific in vivo cytotoxicity induced by AdVOVA  
To assess the functional effect of CD8+ T cells, we performed an in vivo cytotoxicity assay. We 
used OVAI peptide-pulsed splenocytes which had been strongly labeled with CFSE (CFSEhigh); 
and the control peptide Mut1-pulsed splenocytes which had been weakly labeled with CFSE 
(CFSElow) as OVA-specific and control target cells. These target cells at 1: 1 ratio were 
introduced into recipient mice that had been vaccinated with AdVOVA. As expected, there was a 
substantial loss (85%) of the CFSEhigh (OVAI peptide pulsed) cells in the AdVOVA-immunized 
mice, whereas little cytotoxicity (8%) was induced in mice immunized with the control AdVnull 
(Fig. 4-3, P<0.05). Our data indicate that AdVOVA vaccine efficiently stimulates CD8+ T-cell 
differentiation into functional OVA-specific CTL effectors. 
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Fig. 4-3 In vivo cytotoxicity induced by AdVOVA. Six days after the immunization, the 
immunized mice were injected i.v. with 2×106 cells, containing a 1:1 mixture of CFSEhigh- and 
CFSElow-labeled splenocytes that had been pulsed with OVAI or Mut1 peptides, respectively; 
after 16 h, the spleens of immunized mice were removed and the percentages of the residual 
CFSEhigh (H) and CFSElow (L) target cells remaining were analyzed by flow cytometry; the value 
in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in the 
spleen; values in parenthese represent the standard deviation; student’s t-test (P<0.05) showed 
AdVova induced higher cytotoxic responses than that of AdVnull; one representative experiment 
of three is shown.  
4.1.3    Preventative antitumor immunity induced by AdVOVA  
To assess preventative antitumor immunity, AdVOVA-immunized mice were challenged s.c. with 
OVA-expressing B16 melanoma BL6-10OVA on day 60 after immunization.  We found that none 
of the immunized mice (0/10) grew visible tumors (Fig. 4-4), indicating that AdVOVA vaccination 
can induce long-term antitumor immunity. 
 
 
Fig. 4-4 AdVOVA stimulation of preventaive ovalbumin (OVA)-specific antitumor immunity 
in wild-type C57BL/6 mice. AdVOVA-immunized C57BL/6 mice were challenged s.c. with 
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BL6-10ova tumor cells on day 60 after immunization. Tumor growth was monitored; one 
representative experiment of two repeats is shown.  
4.1.4    Immune responses induced by AdVneu  
Transgenic (Tg) FVBneuN mice that have neu-specific immune tolerance spontaneously develop 
multiple HER2/neu-expressing breast cancers (Reilly et al.2000; Miller et al. 2004; Czerniecki et 
al. 2007). These Tg mice were extensively used to evaluate HER2/neu-specific 
immunotherapeutics (Ambrosino et al. 2006; Wall et al. 2007; Whittington et al. 2008). To 
assess CD8+ T cell responses, peripheral blood samples from the mice immunized with AdVneu, 
were harvested on day 11 after immunization, stained with FITC-anti-CD8 Ab and PEanti-H-
2Kq/HER2/neu peptide tetramer, and then analyzed by flow cytometry. We found that AdVneu-
stimulated HER2/neu-specific CD8+ T-cell responses, accounting for 0.63% of the total CD8+ T-
cell population; this was a stronger response than the control mice immunized with AdVnull 
(0.18%, P<0.05, Fig. 4-5). Our data indicate that AdVneu stimulated HER-2/neu-specific CD8+ T-
cell responses in Tg FVBneuN mice with HER2/neu-specific immune tolerance. 
 
Fig. 4-5 Neu-specific CD8+ T cell responses induced by AdVneu. The tail blood samples from 
Tg FVBneuN mice immunized with AdVneu, AdVnull, and PBS as a control,  were harvested at 
day 11 after the immunization, stained with PE-H-2Kq/neuI peptide tetramer and FITC-anti-CD8 
Ab and then analyzed by flow cytometry. Values in each panel represent the percentage of OVA-
specific (tetramer-positive) CD8+ T cells in the total CD8+ T cell population; values in 
parenthese represent standard deviation; student’s t-test (P<0.05) result showed AdVova induced 
higher level of CD8+ T cell responses than that of AdVnull; one representative experiment of two 
is shown. 
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4.1.5    Preventive antitumor immunity induced by AdVneu. 
To determine whether AdVneu-induced cellular immune responses could reduce breast 
carcinogenesis, Tg FVBneuN mice at the age of 2 months were vaccinated s.c. with AdVneu at 1-
month intervals for a total of four vaccinations. As shown in Fig. 4-6, AdVneu vaccination 
protected 3/10 of the mice from breast carcinogenesis; it induced a significant delay in tumor 
formation in 7/10 of the mice compared with the control AdVNull vaccination (P<0.05). Our data 
indicate that AdVneu vaccination can partly overcome self-HER2/neu-specific immune tolerance 
and reduce breast carcinogenesis in Tg FVBneuN mice. 
 
Fig. 4-6 Preventative antitumor immunity induced by AdVneu. Transgenic FVBneuN mice at 
2 months old were vaccinated s.c. with AdVneu and at 1-month intervals for a total of four 
vaccinations; spontaneous formation of breast tumors was monitored weekly; significant 
differences (P<0.05) were found vs cohorts of the control groups (phosphate-buffered saline 
(PBS) and AdVnull) (log-rank test). One representative experiment of two is shown.  
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4.2       Part B. Study on AdVOVA-P30-transfected DC vaccine in  OVA animal 
model 
4.2.1    Construction of AdVOVA-P30 
The construction of AdVOVA-P30 consists of three steps: 
(i)    Insertion of P30 epitope into OVA gene (named OVA-P30). 
(ii)    OVA-P30 gene was then inserted into plasmid pShuttle-CMV (name pShuttle-CMV-
OVA-P30). 
(iii)     pShuttle-CMV-OVA-P30 was transformed into BJ5183 cell to form AdV vector 
pAdEasy-OVA-P30 (Fig. 4-7) by homologous recombination.  
 
Fig. 4-7 Constructed plasmid DNA for AdVOVA-P30. The E1/E3-deleted replication-deficient 
AdV vectors are under the regulation of the CMV early/immediate promoter/enhancer from 
pShuttle-CMV-OVA-P30; the diagram shows the linearized plasmid DNA pAdEasy-OVA-P30. 
4.2.2    Expression of OVA-P30 
Expression of OVA-P30 was determined by Western blot. Linear pAdEasy-OVA-P30 was firstly 
transfected into a 293 cell line (293-26 a cell expressing adenovirus type 5E1/E3 gene). Ten days 
later, proteins were obtained from cell lysates, and analyzed by Western blotting. Lysates from 
cells transfected with linear pAdEasy-pshuttle-CMV vector, as well as cells with no transfection 
were used as control. Results showed that OVA-P30 was highly expressed within the 293 cell 
line that had been transfected with linear AdVOVA-P30 (Fig. 4-8).  
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Fig. 4-8 Expression of OVA-P30 in 293 cells. Transfected 293 cells, as well as control cells 
were analyzed by western blot, using antibodies for expression of OVA and β-actin. Results were 
scanned by LI-COR Odyssey-CLx machine. 
4.2.4    Assessment of OVA-specific CTL responses  induced by the engineered 
DCOVA-P30 vaccine  
4.2.4.1    Generation of AdVOVA and AdVOVA-P30-engineered DC cell vaccines 
Mature dendritic cells (DCs) were prepared by culturing bone-marrow cells for six days with 
DCI and DCII medium containing GM-CSF and IL4 (for detailed procedure, refer to 3.2.3.1). 
DCs were then transfected with AdVOVA or AdVOVA-P30, at the ratio of DC: adenovirus = 1:200 
for 18 hrs in culture medium (for detailed procedure, refer to 3.2.3.2), to form DCOVA and 
DCOVA-P30. Transfected DCOVA and DCOVA-P30 were phenotypically analyzed by flow cytometry 
(for detailed procedure, refer to 3.2.3.3). We found that, similar to the mature DCs, transfected 
DCOVA and DCOVA-P30 expressed DC marker CD11c, a high amount of  MHC class II molecule 
IAb and the costimulatory molecule CD80, indicating that they are mature DCs (Fig. 4-9).  
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Fig. 4-9 Expressions of surface molecules on mature DC cells. Phenotypic changes of DCs, 
AdVOVA-P30 transduced DC (DCOVA-P30) and AdVneu transduced DC (DCOVA) were analyzed by 
flow cytometry, using anti-MHC class II (IAb), CD11c, CD54, CD80 Abs and FITC-labeled goat 
anti-mouse Ab (solid lines); isotype-matched mAbs (dotted lines) were used as controls. Data 
from one experiment of replicate experiments is shown. 
4.2.4.2     T cell immune responses induced by engineered DCOVA-P30 vaccine  
C57/BL6 mice were injected i.v. with either DCOVA or DCOVA-P30. Splenocytes from each 
treatment group were stained with PE-anti-CD44 Ab and FITC-anti-CD4 Ab for assessment of 
CD4+ T cell responses at day 1 or 2 after the immunization. At day 6, 50 μl of peripheral blood 
from immunized mice was stained with PE-H-2Kb/OVAI tetramer and FITC-anti-CD8 Ab for 
assessment of OVA-specific CD8+ T cell responses.  
We found that both DCOVA and DCOVA-P30 vaccines stimulated CD4+ T cell responses (see Fig.4-
10). However, the CD4+ T cell response, induced by DCOVA-P30, (6.14%) were significantly 
higher than those of DCOVA (4.34%) (Fig. 4-10, P<0.05), indicating that the universal foreign Th 
epitope P30 could enhance CD4+ T cell responses in vivo. Both DCOVA and DCOVA-P30 vaccines 
also stimulated efficient OVA-specific CD8+ T cell responses (Fig. 4-11, P<0.05). CTL 
responses induced by DCOVA-P30 (8.52%) were also significantly higher than those of DCOVA 
(4.66%) (Fig. 4-11, P<0.05), indicating that the universal foreign Th epitope P30 also enhanced 
CD8+ T cell responses. 
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Fig. 4-10 CD4+ T cell responses induced by DCOVA and DCOVA-P30. Splenocytes of C57BL/6 
mice immunized with 0.5×106 DCOVA-P30 or DCOVA or DC as a control were harvested at day 1 
after the immunization, stained with PE-anti-CD44 Ab and FITC-anti-CD4 Ab and then 
analyzed by flow cytometry. Values in each panel represent the percentage of activated CD4+ T 
cells in the total CD4+ T cell population; values in parenthese represent standard deviation amd 
student’s t-test showed that the responses derived from DCOVA-P30 were significant higher than 
those of DCOVA (P<0.05). Data from one experiment of three experiments is shown. 
 
Fig. 4-11 OVA-specific CD8+ T cell responses induced by DCOVA and DCOVA-P30. Tail blood 
samples from C57BL/6 mice immunized with DCOVA-P30 vs. control with DCOVA or DCs were 
harvested one day 6 after immunization, stained with PE-H-2Kb/OVAI peptide tetramer and 
FITC-anti-CD8 Ab and then analyzed by flow cytometry. Values in each panel represents the 
percentage of OVA-specific (tetramer-positive) CD8+ T cells in the total CD8+ T cell population. 
Values in parentheses represent standard deviation; student’s t-test showed that the responses 
derived from DCOVA-P30 were significant (P<0.05) higher than those of DCOVA. Data from one 
experiment of three experiments is shown. 
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4.2.5    Vaccine studies 
4.2.5.1     Assessment of in vivo cytotoxicity 
To assess the cytotoxicity of activated CD8+ T cells, in vivo cytotoxicity assays were performed. 
C57BL/6 mouse spleen cells, pulsed with OVAI peptide, were strongly labeled with carboxyl-
fluorescein succinimidyl ester (CFSE) (3.0 mM, CFSEHigh) and served as OVA-specific target 
cells; spleen cells pulsed with irrelevant peptide Mut1 were weakly labeled with CFSE (0.6 mM, 
CFSELow) and served as nonspecific control target cells. Eleven days following the immunization 
with AdVOVA, the immunized mice were then injected i.v. with a 1:1 (CFSEHigh: CFSELow) 
mixture of splenocyte targets. Sixteen hours after target cell delivery, spleens of the recipient 
mice were removed and the relative proportions of CFSEhigh and CFSElow target cells, remaining 
in the splenocytes, were analyzed by flow cytometry.  
There was a substantial loss of the CFSEHigh-labeled OVA-specific target spleenocytes in mice, 
immunized with either DCOVA or DCOVA-P30, indicating that both DCOVA- and DCOVA-P30-
stimulated CD8+ T cells, differentiated into effector CTLs (Fig. 4-12). However, the loss of the 
CFSEHigh-labeled OVA-specific target spleenocytes in mice immunized with  DCOVA-P30 (89%) 
was significantly more than the loss of the CFSEHigh-labeled OVA-specific target splenocytes in 
mice immunized with DCOVA (71%) (P<0.05); thus DCOVA-P30 vaccines triggered more efficient 
CTL responses than DCOVA.  
 
Fig. 4-12 In vivo cytotoxicity induced by DCOVA and DCOVA-P30. Splenocytes from  mice 
immunized were analyzed for the percentage of CFSEHigh vs CFSELow target cells remaining in 
the spleens. Values in each panel represents the percentage of CFSEHigh vs CFSELow target cells 
remaining in the spleen; values in parentheses represent standard deviation; analysis with a 
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student’s t-test showed that the responses induced by DCOVA-P30 were significant (P<0.05) higher 
than those of DCOVA; one representative experiment of three is shown. 
4.2.5.2     Protective antitumor immunity induced by DCOVA-P30 vaccine 
To assess protective antitumor immunity, mice were vaccinated with either DCOVA, DCOVA-P30, 
or control DCs. OVA-expressing melanoma BL6-10OVA cells (3×105/mouse) were injected i.v. 
six days later, and 21 one days after tumor injection, mice were killed and the lungs examined.  
Our data showed that both DCOVA and DCOVA-P30 vaccines protected all mice from BL6-10OVA 
lung metastasis (Fig. 4-13 and Table 4-1). 
 
Fig. 4-13 Preventaive effect of DC immunization on BL6-10OVA melanoma metastasis in 
lungs of mice. C57BL6 mice were immunized either with DC, DCOVA or DCOVA-P30 vaccines, 
and were then challenged with BL6-10OVA melanoma six days post-immunization. Mice were 
monitored for the next 21 days and photographs of representative lung samples from each group 
were shown.  
Table 4-1 BL6-10OVA melanoma colonies in lungs from mice immunized with DCOVA and 
DCOVA-P30  
Vaccine Tumor Bearing Mice (%) Mean # of metastatic tumor colonies 
DCOVA-P30 0/8 (0%) 0 
DCOVA 0/8 (0%) 0 
DC     8/8 (100%) >300 
Three different C57BL6 mice groups, immunized either with DC, DCOVA or DCOVA-P30 vaccines 
were challenged with BL6-10OVA melanoma six days post-immunization; mice were monitored 
for the next 21 day afterwards. One representative experiment of two is shown.  
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4.2.5.3     Therapeutic antitumor immunity induced by DCOVA-P30 vaccine 
To assess therapeutic antitumor immunity, BL6-10OVA cells (3×105) were injected i.v. into mice. 
Three days after tumor challenge, mice (n=8/group) were immunized i.v. with either with DCs, 
DCOVA or DCOVA-P30. Mice were killed 21 days after vaccination and the lungs examed.     
The average number of tumor metastasis colonies, found in the lungs of mice immunized with 
DCOVA-P30, was 25, much fewer than the average number of 137 tumor metastasis colonies 
observed in the lungs of mice immunized with DCOVA (P<0.05). Thus, DCOVA-P30 induced more 
efficient therapeutic antitumor immunity against 3-day established tumors than DCOVA (Fig. 4-14 
and Table 4-2).  
 
Fig. 4-14 Therapeutic effect of DCOVA and DCOVA-P30 vaccines agaist BL6-10OVA melanoma 
metastasis in lungs of mice. C57BL6 mice (n=8) were challenged with BL6-10OVA melanoma 
and then were immunized with DC, DCOVA and DCOVA-P30 three days later. Lungs were collected 
after 21 days. Photographs of representative lung samples from each group are shown; small 
black nodes in the lung represent lung melanoma metastasis colonies.  
Table 4-2 Metastatic tumor colonies in lungs of mice immunized with DCOVA and DCOVA-P30  
Vaccine Tumor Bearing Mice (%) Mean # of metastatic tumor colonies  
DCOVA-P30 8/8 (100%) 25 (16-35)* 
DCOVA 8/8 (100%) 137 (118-156) 
DC 8/8 (100%) >300 
C57BL6 mice were challenged with BL6-10OVA melanoma; and 3 days later immunized with 
either DC, DCOVA or DCOVA-P30. Lungs were collected after 21 days. Values in parenthese 
represent range of values; student’s t-test showed that the responses derived from DCOVA-P30 were 
significant(P<0.05)  higher than those of DCOVA. One representative experiment of two is shown.  
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4.3 Part C. Study on AdVneu-P30-transfected DC vaccine in the neu animal 
model 
4.3.1    Construction of AdVneu-P30 
The construction of AdVneu-p30 consisted of three steps: 
(i)      Insertion of P30 gene into the neu gene (named neu-p30). 
(ii)      neu-p30 gene was then inserted into the plasmid pShuttle-CMV (name pShuttle-
CMV-neu-P30). 
(iii)     pShuttle-CMV-neu-P30 was transformed into the BJ5183 cell to form AdV vector 
pAdEasy-neu-P30 by homologous recombination (Fig. 4-15).  
 
Fig. 4-15 Constructed plasmid DNA for AdVneu-P30. The E1/E3-deleted replication-deficient 
AdV vectors are under the regulation of the CMV early/immediate promoter/enhancer from 
pShuttle-CMV-neu-P30; the diagram shows the linearized plasmid DNA AdEasy-neu-P30. 
4.3.2    Expression of neu-P30 
After 293 cells were transfected with linear plasmid pAdEasy-pshuttle-CMV-neu-P30 (or 
pAdEasy-neu-P30), virions (AdVneu-P30) were released into the culture media and purified by 
differential ultracentrifugation. The purified AdVneu-P30 (5×1010 PFU/mL) was stored at -80°C for 
future use. Neu-p30 gene expression in 293 cells was detected by flow cytometry, using anti-neu 
antibody 24 hr after AdVneu-P30 infection. The 293 cells without transfection were used as a 
negative control. The 293 cells, infected with AdVneu-P30, expressed a much higher level of neu 
than the cells without infection, indicating AdVneu-P30 was functional (Fig. 4-16). 
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Fig. 4-16 Expression of neu. AdVneu-p30 transfected 293 cells (293neu) as well as the control 
293 cells were analyzed by flow cytometry, using the anti-neu antibody (solid lines) and an 
irrelevant isotype-matched control antibody (dotted lines). Data from a single analysis is shown. 
4.3.3    Immune response derived from engineered DCneu-P30 vaccine 
4.3.3.1     Generation of AdVneu and AdVneu-P30-engineered DC cell vaccine 
Mature DC cells were prepared by culturing bone marrow cells for six days with DCI and DCII 
medium containing GM-CSF and IL4 (see detailed procedure in section 3.2.3.1). DCs were then 
transfected with AdVneu or AdVneu-P30 using a DC: adenovirus ratio= 1:200 for 18 hrs to generate 
DCneu and DCneu-P30 (see detailed procedure in section 3.2.3.2). Transfected DCneu and DCneu-P30 
were phenotypically analyzed by flow cytometry (detailed procedure refer to 3.2.3.3). Similar to 
mature DCs, transfected DCneu and DCneu-P30 also expressed the DC marker CD11c, a high level 
of  MHC class II molecule IAb and the costimulatory molecule CD80, indicating that they are 
mature DCs (Fig. 4-17). DC cells infected with AdVneu or AdVneu-P30 express high level of neu. 
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Fig. 4-17 Expressions of DC molecules and neu on mature DC cell. The phenotype of DCs, 
DCneu-P30, and DCneu were analyzed by flow cytometry, using anti-neu, anti-CD11c, anti-CD54 
and anti-CD80 Abs dectected with FITC-labeled goat anti-mouse Ab (solid lines). Isotype-
matched mAbs (dotted lines) were used as controls. 
4.3.3.2     Immune response induced by engineered DC neu-P30 cell vaccine  
The transgenic FVBneuN mice were i.v. immunized with DCneu or DCneu-P30. Splenocytes from 
each mouse group were stained with PE-anti-CD44 Ab and FITC-anti-CD4 Ab for assessment of 
CD4+ T cell responses at day 1 or 2 subsequent to DC immunization. On day 6, peripheral blood 
samples (50 µl) derived from immunized mice were stained with PE-anti-IFN-γ Ab and FITC-
anti-CD8 Ab for assessment of CD8+ T cell responses.  
We found that both DCneu and DCneu-P30 vaccines stimulated CD4+ T cell responses (Fig. 4-18). 
However, the CD4+ T cell response (5.03%), induced by DCneu-P30, was similar to that of DCneu 
(4.74%). Both DCneu and DCneu-P30 vaccines also stimulated CD44+ and IFN-γ-secreting CD8+ T 
cell responses (Fig. 4-19 and Fig. 4-20). However, the CTL response (3.54% CD8+44+ T; 0.99% 
IFN-γ-secreting CD8+ T) induced by DCneu-P30, was significantly (P<0.05) higher than that DCneu 
(2.55% for CD8+44+ T; 0.42% for IFN-γ-secreting CD8+ T),  indicating that the universal foreign 
Th epitope P30 enhanced CD8+ T cell responses. 
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Fig. 4-18 Activated CD4+ T cell responses induced by DCneu and DCneu-P30. Splenocytes from 
Tg FVBneuN mice, immunized with DCneu-P30, DCOVA, or DC, were harvested one day after 
immunization and were stained with PE-anti-CD4 Ab and FITC-anti-CD44 Ab before analyzing 
with flow cytometry. Values in each panel represent the percentage of activated CD4+ T cells in 
the total CD4+ T cell population. Values in parenthesis represent standard deviation. Data from 
one of two relicate experiment is shown. 
 
 
Fig. 4-19 Activated CD8+ T cell responses induced by DC vaccination. Tail blood samples 
from Tg FVBneuN mice, immunized with DCneu-P30, DCOVA, or DC, were harvested on day 6 
after immunization and stained with PE-anti-CD8 and FITC-anti-CD44 Ab and then analyzed by 
flow cytometry. Values in each panel represent the percent of activated CD8+ T cells in the total 
CD8+ T cell population. Values in parentheses represent standard deviation. Analysis with a 
student’s t-test results showed that responses induced by DCneu-P30 were significant (P<0.05) 
higher than those of DCneu. Data from one of two relicate experiment is shown. 
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Fig. 4-20 IFN-γ secreting CD8+ T cell responses induced by DC vaccination. Tail blood 
samples from Tg FVBneuN mice immunized with DCneu-P30, DCOVA, or DCs, were harvested on 
day 6 after immunization and were stained with PE-anti-CD8 and FITC-anti-IFN-γ Ab after 
permeabilized and then analyzed by flow cytometry. Values in each panel represent the percent 
of IFN-γ secreting CD8+ T cells in the total CD8+ T cell population. Values in parenthesis 
represent standard deviation. Analysis with a student’s t-test results showed that the responses 
derived from DCneu-P30 were significant (P<0.05) higher than those of DCneu; Data from one of 
two relicate experiment is shown. 
4.3.3.3     Protective immunity induced by DCneu-P30 vaccine 
To assess protective immunity, three groups of transgenic FVBneuN mice were vaccinated with 
DCneu, DCneu-P30, or DCs, respectively. Neu-expressing Tg1-1 cells (3×105 or 1×106) were 
injected i.v. into each group of mice six days later. Mice were killed 21 days after tumor 
injection and the lungs collected for observation.   
Both DCneu- and DCneu-P30-vaccinated mice were protected against Tg1-1 tumor cell challenge 
(3×105) (see Fig. 4-21 and Table 4-3). However, when immunized mice were challenged with 
Tg1-1 tumor cells (1×106), the average number of lung tumor metastasis colonies in mice, 
immunized with DCneu-P30, was 16. The average number of lung tumor metastasis colonies was 
144 in mice, immunized with DCneu (Fig. 4-22 and Table 4-4), indicating that DCneu-P30 vaccine 
induces more efficient antitumor immunity in Tg FVBneuN mice with neu-specific immune 
tolerance.  
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Fig. 4-21 Prevention of Tg1-1 (0.3 M) tumor metastasis in lungs of DCneu and DCneu-P30 
immunized mice.Tg FVBneuN mice immunized with DC, DCneu or DCneu-P30, were challenged 
with Tg 1-1 tumor cells (3×105) six days post-immunization. Mice were killed 21 days after 
tumor cell challenge. Photographs of representative lung samples from each group are shown. 
(A) Tumor clonies (white) are shown and indicated by arrows. (B) Histology of of lungs 
(magnification=100×).  
 
Table 4-3 Metastatic tumor colonies in lungs from FVBneuN mice immunized with DCneu 
and DCneu-P30 (a) 
Vaccine Tumor Bearing Mice (%) Mean # of metastatic tumor colonies 
DCneu-P30 0/8 (0%) 0 
DCneu 0/8 (0%) 0 
DC 8/8 (100%) 123 (112-134) 
Tg FVBneuN mice were immunized with either DCs, DCneu or DCneu-P30.  Immunized mice were 
then challenged i.v. with Tg1-1 cancer cells (3×105) six days after immunization. Mice were 
killed 21 days after tumor cell challenge and lungs were examined for white tumor colonies. 
Data form one experiment of two replicate experiments is shown. 
 
 82 
 
 
Fig. 4-22 Prevention of Tg1-1(1 M) tumor metastasis in lungs of DCneu and DCneu-P30 
immunized mice. Tg FVBneuN mice, immunized with either DCs, DCneu or DCneu-P30, were then 
challenged with Tg 1-1 tumor cells (1×106) six days post-immunization. Mice were killed 21 
days after tumor cell challenge. (A) Photographs of representative lung samples from each group 
are shown. Tumor clonies (white) were shown and indicated by arrows. (B) Histology of lungs 
(magnification=100×). 
 
Table 4-4 Metastatic tumor colonies in lungs from FVBneuN mice immunized with DCneu 
and DCneu-P30 (b) 
Vaccine Tumor Bearing Mice (%) Mean # of metastatic tumor colonies 
DCneu-P30 8/8 (100%) 16 (12-20)* 
DCneu 8/8 (100%) 144 (128-160) 
DC 8/8 (100%) >300 
Tg FVBneuN mice were immunized with either DC, DCneu or DCneu-P30. Immunized mice were 
then challenged i.v. with Tg1-1 cancer cells (1×106) six days after immunization. Mice were 
killed 21 days after tumor cell challenge and lungs were examined for white tumor colonies. 
Student’s t-test results showed that the CTL responses derived from DCneu-P30 were significant 
(P<0.05) higher than those of DCneu. Data form one experiment of two replicate experiments is 
shown. 
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The results derived from DCneu-P30 and DCneu vaccinations demonstrated that DCneu-P30 
vaccine stimulated stronger CD8+ T cell responses and antitumor immunity than that of DCneu 
vaccine. Our data indicate that the universal Th epitope P30 enhances CD8+ T cell responses, 
leading to antitumor immunity in Tg FVBneuN mice by breaking self-immune tolerance. 
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5   Discussion 
Conventional cancer therapies, including surgery, radiation therapy and chemotherapy have 
demonstrated considerable clinical success in the past. However, tumor-free survival is not 
always accomplished. For example, surgery and radiation therapy are quite effective in treatment 
of localized tumors but they often have only a palliative role in treatment of disseminated 
diseases. Chemotherapy remains the treatment modality of choice but severe toxic side-effects 
often limit its use.  
The identification of tumor-associated Ags and tumor-specific T-cell responses in cancer patients 
led to the development of immunotherapies, aimed at augmenting antitumor immune responses. 
Antitumor immunotherapies include: 1) active immunotherapy, such as the use of various 
antitumor vaccines to stimulate the patients’ antitumor CD8+ CTL responses (Antonia et al. 
2004), and 2) adoptive immunotherapy, such as infusion of the antitumor monoclonal Ab 
trastuzumab or tumor-specific tumor-infiltrating lymphocytes (Gonzalez-Angulo et.al, 2006; 
Knutson  et al. 2005). 
The original anti-HER-2/neu murine monoclonal antibodies inhibited HER-2/neu-positive tumor 
growth in vivo (Harwerth et al. 1993; Knutson et al. 2004; Hudziak et al. 1989) Trastuzumab is a 
humanized monoclonal Ab, directed against the extracellular domain of HER-2/neu. Its use, in 
combination with chemotherapy, was approved by the FDA in 1998 for metastatic HER-2/neu 
overexpressing breast cancer (Slamon et al. 2001). Preclinical studies demonstrated interesting 
properties of trastuzumab, including  internalization and degradation of the HER-2 protein 
(Molina et al. 2001), inhibition of cell-cycle progression via inhibition of the mitogen-activated 
protein kinase pathway (Le  et al. 2003; Jackson et al. 2004), suppression of the anti-apoptotic 
phosphatidylinositol 3-kinase and Akt pathway (Yakes et al. 2002; Mohsin et al. 2005) and Ab-
dependent cellular cytotoxicity (Clynes  et al. 2000; Gennari et al. 2004). Clinical studies showed 
that approximately one third of patients with advanced HER-2/neu-positive breast cancer will 
respond to trastuzumab monotherapy (Vogel et al. 2002; Cobleigh et al.1999). Trastuzumab-
based therapy has also been shown to be effective in both adjuvant and neo-adjuvant setting in 
the management of early stage HER-2/neu-positive breast cancer (Baselga et al. 2004; Buzdar et 
al.2005). However, one of the major limitations of trastuzumab immunotherapy is the 
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development of Ab resistance, usually within one year from the beginning of treatment in the 
metastatic setting (Nahta et al. 2006; Berns et al.2007). Thus, there is a need to search for other 
therapeutic strategies.  
One of the most remarkable features of AdV-based vaccines is their ability to induce 
exceptionally high and sustained frequencies of transgene product-specific CD8+ T-cell 
responses; unlike those induced by other subunit vaccine carriers such as DNA vaccines or 
poxvirus vectors, these CD8+ T cells do not contract after the initial CTL activation (Bruna-
Romero et al. 2001; Hassett et al.2000). The replication-defective AdV vector genome is similar 
to those of wild-type AdV vectors (Tatsis et al. 2007; Yang et al. 2006). These replication-
defective AdV vectors have been found in the muscle at the site of inoculation, in the liver and in 
the lymphatic tissues of experimental animals (Tatsis et al. 2007; Yang et al. 2006). 
In this study, we also demonstrated that AdVOVA vaccination induced sustained CD8+ CTL 
responses due to persistent Ag stimulation, leading to 100% protection from tumor cell 
challenge, which is consistent with previous reports by others (Tatsis et al. 2007; Yang et al. 
2006). The AdVneu vaccination stimulated both HER-2/neu-specific Ab and CD8+ CTL responses 
and preventive antitumor immunity in wild-type mice (Gallo et al. 2005; Park et al. 2005; Wang 
et al. 2005). However, it does not reduce breast carcinogenesis in Tg mice with self-immune 
tolerance though their survival was prolonged (Millar et al. 2007; Kianizad et al. 2007). In this 
study, we demonstrated that AdVneu induced neu-specific functional CD8+ T cell responses and 
that AdVneu vaccination can reduce breast carcinogenesis in Tg FVBneuN mice with self-
immune tolerance, consistent with another recent report by Berzofsky et al. (Grinshtein et al. 
2009). The more effective reduction in breast carcinogenesis by our AdVneu vaccine in Tg 
FVBneuN mice may possibly be due to more efficient transfection by our AdVneu with fiber 
gene modification (Sas et al. 2008). Thus, more efficient transgene neu expression occurs. The 
AdVneu without fiber gene modification that was used by others (Millar et al. 2007; Kianizad et 
al. 2007).   
It is generally believed that CD4+ and CD8+ T cells recognizing self-antigens, including many 
tumor Ags, with high affinity in the thymus, are deleted (Sprent et al. 2002; Sprent et al.2003). 
Therefore, vaccination attempts to break immunological tolerance may be hampered. 
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Understanding the mechanisms behind tolerance is paramount for understanding the fundamental 
concepts in immunology, as well as for vaccine development. CD4+ T helper cells play crucial 
roles in priming, expansion, and memory development of both B cell and CD8+ CTL responses. 
The critical role of Th cells is well documented and is found to be essential in antitumor 
immunity (Dalum et al. 1996; Dalum et al. 1999; Hertz et al. 2001; Renard et al. 2003).  
The tetanus toxin epitope, P30 (FNNFTVSFWLRVPKVSASHLE) is a universally immunogenic 
epitope, capable of stimulating CD4+ T cell responses (Panina-Bordignon et al. 1989). The 
HER2/neu DNA vaccine, containing the potent Th cell epitope P30, induced complete immune 
protection against tumor cell challenge in wild-type mice but only partial antitumor protection in 
Tg mice. The HER2/neu protein vaccine, containing P30 epitope, stimulated protective immune 
responses even in Tg mice (Renard et al. 2003). In an OVA model study, vaccination with DNA, 
containing P30, prevented the growth of OVA-expressing tumor in transgenic rat insulin 
promoter (RIP)-mOVA mice (Steinaa et al. 2005). A membrane bound truncated OVA sequence 
under the control of RIP was found in pancreatic islets as well as in the kidney proximal tubules, 
thymus and the testis of male mice (Kurts et al. 1996) and also exhibited deletional tolerance 
toward the OVA265–280 (SIINFEKL, MHC class I epitope of OVA) epitope (Kurts et al. 1997). 
Thus, the foreign Th epitope P30 broke CD8+ T cell tolerance against self Ag in these Tg mice. 
In this study, we constructed recombinant AdVOVA-P30, expressing ovalbumin (OVA)-P30 and 
AdV-transfected DC (DCOVA-P30) vaccine  by transfection of BM-derived DCs with AdVOVA-P30. 
We immunized C57BL/6 mice with DCOVA-P30 and then assessed CD4+ and CD8+ T cell 
responses and antitumor immunity, after immunization. We demonstrated that DCOVA-P30 was 
capable of stimulating both enhanced OVA-specific CD4+ and CD8+ T cell responses, leading to 
preventive antitumor immunity against OVA-expressing BL6-10OVA tumor cell challenge in 
immunized C57BL/6 mice (100%); and significant therapeutic antitumor immunity against 
OVA-expressing BL6-10OVA tumors established 3 days prior to immunization in C57BL/6 mice.  
HER2/neu has proven to be an attractive Ag for immunotherapeutic targeting (Yarden 2001; 
Yarden and Sliwkowski 2001).  DNA vaccines, expressing full length HER2 or partial length 
(ECD or ICD) of HER2, induced HER2-specific humoral and T cell immune responses (Amici et 
al. 1998, Chen et al. 1998, Piechocki et al. 2001, Pilon et al. 2001). However, they were not able 
to convey any beneficial therapeutic effects in HER2/neu transgenic (Tg) mice (Amici et al. 
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1998, Foy et al. 2001; Quaglino et al. 2004a; Radkevich-Brown and Jacob et al. 2009). DCs are 
the most powerful and efficient antigen-presenting cells (APCs). They are largely responsible for 
priming T cell responses (Zinkernagel 1974; Linsley et al. 2002). DCs, engineered to express 
tumor antigens, have been widely studied and utilized as cancer vaccines that generate an 
effective antitumor immune response both in murine models and in human clinical studies 
(Koski et al. 2008).  
We previously showed that AdVneu-transfected DCneu vaccine induced more efficient 
preventive antitumor immunity against neu-expressing Tg1-1 tumor challenge s.c. than OVA-
expressing DNA vaccine in wild-type FVB/NJ mice (Chan et al. 2006). Later, we constructed 
DCneu vaccine by transfection of DCs with  fibre-modified RGDAdVneu and showed that  
recombinant RGDAdVneu with fibre gene, modified by RGD insertion to the viral knob’s H1 
loop, had enhanced transfection of DCs, lacking coxsackievirus and AdV receptor (CAR), 
leading to enhanced transgene neu expression in DCneu (Sas et al. 2008). We demonstrated that 
RGDAdVneu-transfected DCneu stimulated more efficient antitumor immunity than AdVneu-
transfected DCneu in wild-type FVB/NJ mice; however, it still failed to protect transgenic 
FVBneuN mice from Tg1-1 tumor challenge (Sas et al. 2008). In this study, we constructed 
recombinant AdVneu-P30, expressing HER2/neu-P30, and AdV-transfected DC (DCneu-P30) vaccine 
by transfection of BM-derived DCs with AdVneu-P30. We immunized transgenic FVBneuN mice 
with DCneu-P30 and then assessed CD4+ and CD8+ T cell responses and antitumor immunity 
subsequent to immunization. We demonstrated that DCneu-P30 were capable of stimulating 
enhanced CD8+ T cell responses, leading to preventive antitumor immunity against the challenge 
of neu-expressing Tg1-1 tumor cells (3×105) in 100% (8/8) immunized transgenic FVBneuN 
mice; this treatment also significantly reduced lung metastasis tumor colonies in  immunized 
transgenic FVBneuN mice, challenged with Tg1-1 tumor cells (1×106). Thus, incorporation of 
the foreign CD4+ Th epitope P30 into a DC-based vaccine at least partially broke self-immune 
tolerance, leading to enhanced CTL responses and antitumor immunity in transgenic FVBneuN 
mice. 
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6   Conclusion and future direction  
Our data demonstrated that CD4+ Th epitope P30 enhanced both CD4+ and CD8+ T cell 
responses, leading to enhanced DC-stimulated antitumor immunity. This may impact the design 
of new DC-based vaccines for the treatment of breast cancer and other types of human 
malignancies. 
Conventional anti-cancer therapies, surgery, radiationtherapy and/or chemotherapy, have gained 
considerable clinical success in the past. Because of the limitations, imposed by current 
treatments, tumor-free survival is not always accomplished. For instance, surgery and 
radiationtherapy are quite effective in the treatment of localized tumors but they can only play a 
palliative role in the treatment of disseminated diseases. Chemotherapy in these cases remains 
the treatment modality of choice but severe toxic effects toward normal tissues often limit its use. 
The identification of tumor antigens and tumor specific T cell responses in cancer patients led to 
the development of immunotherapies, aimed at augmenting antitumor immune responses. Many 
preclinical studies indicated that both active and adoptive immunotherapies were quite effective 
against small tumor burdens but incapable of controlling large tumor masses. 
 The major limitation for combining chemotherapy and immunotherapy is that the 
chemotherapeutic drugs are generally immunosuppressive because the drugs are toxic to the 
dividing immune stem cells in the bone marrow. 
In our study, CD4+ Th epitope P30 enhanced both CD4+ and CD8+ T cell responses, leading to 
enhanced DC-stimulated antitumor immunity. However, our engineered DCneu-P30 vaccine 
induced only partial immune protection against challenge of a small (3×105) and large (1×106) 
amounts of Tg1-1 tumor cells, in transgenic FVBneuN mice. Therefore, a therapeutic effect 
against established tumors may require a combination of chemotherapy to eradicate of the tumor 
masses along with active specific immunotherapy such as DC vaccine to eliminate potential 
tumor metastasis. Such a protocal may have great potential for the treatment of cancer patients, 
but needs to be further confirmed in larger controlled and randomized trials in the future.  
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